6-K - MDXH - Equibles

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TORULE 13a-16 OR 15d-16UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of June 2023

Commission File Number 001-40996

MDXHEALTH SA

(Translation of registrant’s name into English)

CAP Business Center

Zone Industrielle des Hauts-Sarts

4040 Herstal, Belgium

+32 4 257 70 21

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

MDXHEALTH SA

MDxHealth SA (the “Company”) hereby furnishes the attached documents in connection with its Extraordinary General Shareholders’ Meeting to be held on Friday, June 30, 2023 at 9:00 a.m., Belgian time, at the offices of the notary public Stijn Raes, at Kortrijksesteenweg 1147, 9051 Ghent, Belgium, or at such other place as will be indicated at that place at that time.

The informationin the attached Exhibits 99.1-99.9 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of theSecurities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section,nor shall they be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, orthe Exchange Act, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.

Exhibit No.	Description of Exhibit
99.1	Convening Notice
99.2	Attendance Form
99.3	Proxy Form
99.4	Voting by Mail Form
99.5	Outstanding Shares and Voting Rights
99.6	Press Release, dated June 5, 2023

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	MDXHEALTH SA
Date: June 6, 2023	By:	/s/ Michael McGarrity
		Name:	Michael McGarrity
		Title:	Chief Executive Officer

Exhibit 99.1

Unofficial Englishtranslation – For informational purposes only

MDxHealth SA

Limited Liability Company(société anonyme)

CAP Business Center

Zone Industrielle des Hauts-Sarts

Rue d’Abhooz 31

4040 Herstal, Belgium

VAT BE 0479.292.440 (RLP Liège, division Liège)

INVITATION

EXTRAORDINARY GENERAL MEETINGto be held on Friday, 30 June 2023, at 9:00 a.m.

As the quorum for the deliberation and voting on the matters on the agenda of the extraordinary general shareholders’ meeting of MDxHealth SA (the “Company”) held on 25 May 2023 was not reached, the holders of securities of the Company are invited to attend a second extraordinary general shareholders’ meeting of the Company before a notary public.

GENERAL INFORMATION

Date, hour and venue: The extraordinary general shareholders’ meeting will be held on Friday, 30 June 2023 at 9:00 a.m. at the offices of the notary public Stijn Raes, at Kortrijksesteenweg 1147, 9051 Ghent, Belgium, or at such other place as will be indicated at that place at that time.

Opening of the doors: In order to facilitate the keeping of the attendance list on the day of the extraordinary general shareholders’ meeting, holders of securities and their representatives are invited to register as of 8:15 a.m.

EXTRAORDINARY GENERAL MEETING

**Agenda and proposed resolutions:**The agenda and proposed resolutions of the extraordinary general shareholders’ meeting of the Company which, as the case may be, can be amended at the meeting on behalf of the board of directors, are as follows:

1.	Submission of reports - 2023 Share Option PlanSubmission of, discussion on:
(a)	the report of the board of directors of the Company in accordance with articles<br>7:180 and 7:191 of the Belgian Companies and Associations Code in relation to the proposal to issue 5,000,000 new subscription rights<br>for shares of the Company (the “2023 Share Options”), pursuant to a share option plan named “the 2023 Share Option<br>Plan”, and to dis-apply, in the interest of the Company, the preferential subscription right of the existing shareholders of the<br>Company and, insofar as required, of the holders of outstanding subscription rights (share options) or American Depositary Shares (“ADSs”)<br>of the Company, for the benefit of the members of the personnel of the Company and its subsidiaries from time to time, within the meaning<br>of article 1:27 of the Belgian Companies and Associations Code (the “Selected Participant”); and
---	---
(b)	the report of the statutory auditor of the Company in accordance with articles<br>7:180 and 7:191 of the Belgian Companies and Associations Code in relation to the proposal to issue 5,000,000 2023 Share Options, and<br>to dis-apply, in the interest of the Company, the preferential subscription right of the existing shareholders of the Company and, insofar<br>as required, of the holders of outstanding subscription rights (share options) or ADSs of the Company, to the benefit of the Selected<br>Participants.
---	---

UnofficialEnglish translation – For informational purposes only

2.	Proposal to issue 5,000,000 2023 Share Options

Proposed resolution: The general shareholders’ meeting resolves to approve the issuance of 5,000,000 2023 Share Options, pursuant to a share option plan named the “2023 Share Option Plan”, and to dis-apply, in the interest of the Company, the preferential subscription right of the existing shareholders of the Company and, insofar as required, of the holders of outstanding subscription rights (share options) or ADSs of the Company, for the benefit of Selected Participant. In view thereof, the general shareholders’ meeting resolves as follows:

(a)	Terms and conditions of the 2023 Share Options: The terms and conditions<br>of the 2023 Share Options (including, but not limited to, the exercise price of the 2023 Share Options) shall be as set out in the annex<br>to the report of the board of directors referred to in item 1.(a) of the agenda (for the purpose of this resolution, the “Plan”),<br>a copy of which shall remain attached to the minutes reflecting the present resolution. The 2023 Share Options have a term of ten years<br>as from their issue date.
(b)	Underlying shares: Each 2023 Share Option shall entitle the holder thereof<br>to subscribe for one new share to be issued by the Company. The new shares to be issued at the occasion of the exercise of the 2023 Share<br>Options shall have the same rights and benefits as, and rank pari passu in all respects, including as to entitlements to dividends<br>and other distributions, with the existing and outstanding shares of the Company at the moment of their issuance, and will be entitled<br>to dividends and other distributions in respect of which the relevant record date or due date falls on or after the date of issue of the<br>shares.
---	---
(c)	Dis-application of the preferential subscription right for the benefit of the<br>Selected Participants: The general shareholders’ meeting resolves, in accordance with article 7:191 of the Belgian Companies<br>and Associations Code, to dis-apply, in the interest of the Company, the preferential subscription right of the existing shareholders<br>of the Company and, insofar as required, of the holders of outstanding subscription rights (share options) or ADSs of the Company, for<br>the benefit of the Selected Participants, and to approve the possibility for the Company to grant the 2023 Share Options to the Selected<br>Participants, as further explained in the report of the board of directors referred to in item 1.(a) of the agenda and the terms and conditions<br>of the Plan.
---	---
(d)	Confirmation of the subscription of 2023 Share Options by the Company: The<br>general shareholders’ meeting resolves to approve and confirm that the Company will be able to subscribe for the 2023 Share Options,<br>with a view to creating a pool of outstanding 2023 Share Options available for further grants to Selected Participants. The Company may<br>not, however, exercise the 2023 Share Options for its own account.
---	---
(e)	Conditional capital increase and issue of new shares: The general shareholders’<br>meeting resolves, subject to, and to the extent of the exercise of 2023 Share Options, to increase the Company’s share capital and<br>to issue the relevant number of new shares issuable upon the exercise of the 2023 Share Options. Subject to, and in accordance with, the<br>provisions of the Plan, upon exercise of the 2023 Share Options and issue of new shares, the aggregate amount of the exercise price of<br>the 2023 Share Options will be allocated to the share capital of the Company. To the extent that the amount of the exercise price of the<br>2023 Share Options, per share to be issued upon exercise of the 2023 Share Options, exceeds the fractional value of the then existing<br>shares of the Company existing immediately prior to the issue of the new shares concerned, a part of the exercise price, per share to<br>be issued upon exercise of the 2023 Share Options, equal to such fractional value shall be booked as share capital, whereby the balance<br>shall be booked as issue premium. Following the capital increase and issuance of new shares, each new and existing share shall represent<br>the same fraction of the share capital of the Company.
---	---
(f)	Issue premium: Any issue premium that will be booked in connection with<br>the 2023 Share Options shall be accounted for on a non-distributable account on the liabilities side of the Company’s balance sheet<br>under its net equity, and the account on which the issue premium will be booked shall, like the share capital, serve as a guarantee for<br>third parties and can only be reduced on the basis of a lawful<br>resolution of the general shareholders’ meeting passed in the manner required for an amendments to the Company’s articles<br>of association.
---	---

UnofficialEnglish translation – For informational purposes only

(g)	Powers of attorney: The board of directors is authorised to implement and<br>execute the resolutions passed by the general shareholders’ meeting in connection with the 2023 Share Options, and to take all steps<br>and carry out all formalities that shall be required by virtue of the Plan, the Company’s articles of association and applicable<br>law in order to issue or transfer the shares upon exercise of the 2023 Share Options. Furthermore, each of the Company’s directors,<br>Joe Sollee and Ron Kalfus, each such person acting individually and with possibility of sub-delegation and the power of subrogation, shall<br>have the power, upon exercise of the 2023 Share Options, (i) to proceed with the recording of (A) the capital increase and issue of new<br>shares resulting from such exercise, (B) the allocation of the share capital and (as applicable) the issue premium, and (C) the amendment<br>of the Company’s articles of association in order to reflect the new share capital and number of outstanding shares following the<br>exercise of the 2023 Share Options, (ii) to sign and deliver, on behalf of the Company, the relevant Euroclear, Euronext and bank documentation,<br>the share register and all necessary documents in connection with the issuance and delivery of the shares to the beneficiary, and (iii)<br>to do whatever may be necessary or useful (including but not limited to the preparation and execution of all documents and forms) for<br>the admission of the shares issued upon the exercise of the 2023 Share Options to trading on the regulated market of Euronext Brussels<br>(or such other markets on which the Company’s shares will be trading at that time).
(h)	Waiver: The general shareholders’ meeting acknowledges that the 2023<br>Share Options to be granted under the “2023 Share Option Plan” shall not be considered “variable remuneration”,<br>“fixed remuneration” or “annual remuneration” within the meaning of the Belgian Companies and Associations Code<br>(including, without limitation, for the purpose of articles 3:6, §3, 7:89/1, 7:90, 7:91, 7:92, 7:100, 7:108 and 7:121 of the Belgian<br>Companies and Associations Code) and the 2020 Corporate Governance Code (including, without limitation, for the purpose of provision 11<br>of the 2020 Corporate Governance Code). The general shareholders’ meeting approves the vesting conditions and mechanisms of the<br>2023 Share Options, as included in the Plan. The provisions of articles 7:91, 7:108 and 7:121 (as applicable) of the Belgian Companies<br>and Associations Code are expressly dis-applied in relation to the 2023 Share Option Plan.
---	---
(i)	Approval in accordance with article 7:151 of the Belgian Companies and Associations<br>Code: The general shareholders’ meeting resolves to take note, approve and ratify, insofar as required in accordance with article<br>7:151 of the Belgian Companies and Associations Code, all clauses included in the Plan, which come into effect at the moment a change<br>of control occurs and which fall or could be considered to fall within the scope of article 7:151 of the Belgian Companies and Associations<br>Code (relating to the granting of rights to third parties that substantially affect the Company’s assets and liabilities, or give<br>rise to a substantial debt or commitment on its behalf, when the exercise of these rights is subject to the launching of a public takeover<br>bid on the shares of the Company or to a change in the control exercised over it), including, without limitation, the automatic accelerated<br>vesting mechanism upon acquisition as defined in the Plan. The general shareholders’ meeting grants a special power of attorney<br>to each director of the Company, acting alone and with power of substitution, for the purpose of carrying out the formalities required<br>by article 7:151 of the Belgian Companies and Associations Code with respect to this resolution.
---	---

3.	Submission of the special report of the board of directors in accordance witharticle 7:199 of the Belgian Companies and Associations Code relating to the proposal to renew the authorised capital

Consideration, discussion and submission of the special report of the board of directors in accordance with article 7:199 of the Belgian Companies and Associations Code relating to the proposal to renew the powers granted to the board of directors under the authorised capital, as set out below in item 4 of the agenda of the extraordinary general shareholders’ meeting, and setting out the specific circumstances in which the board of directors will be able to use its powers under the authorised capital, and the purposes that it should pursue.

UnofficialEnglish translation – For informational purposes only

4.	Renewal of the authorisation to the board of directorsto increase the share capital within the framework of the authorised capital

In order to allow the board of directors the flexibility to raise additional equity-based financing as and when the need may arise or an opportunity would present itself, the board of directors proposes that it be granted limited powers under the authorised capital to increase the Company’s share capital by a maximum amount of 100% during a term of five (5) years, all as further set out below. For further information on the circumstances in which the board of directors could make use of the authorised capital and the objectives that the board of directors would pursue with the authorised capital, see also the special report referred to in item 3 of the agenda of the extraordinary general shareholders’ meeting.

Proposed resolution: The general shareholders’ meeting resolves to renew the authorisation to the board of directors to increase the share capital in one or several times, during a period of five (5) years as from the publication in the Annexes to the Belgian Official Gazette of this authorisation, with an aggregate amount equal to up to 100% of the amount of the share capital of the Company, and this in accordance with the terms and conditions set forth in the special report of the board of directors prepared in accordance with article 7:199 of the Belgian Companies and Associations Code, as referred to in agenda item 3 of this extraordinary general shareholders’ meeting. Consequently, the general shareholders’ meeting resolves to delete article 6 “Authorised capital” of the articles of association of the Company entirely and to replace it with the following text (whereby the date referred to in the sub-section between square brackets shall be the date of the general shareholders’ meeting approving the renewed authorised capital, and the amount referred to in the sub-section between brackets shall be the amount of the Company’s share capital at the time of the general shareholders’ meeting approving the authorised capital):

“Article 6: Authorisedcapital

The board of directors is authorisedto increase the share capital of the company on one or several occasions by a maximum aggregate amount of [100% of the company’sshare capital at the time of the adoption of the new authorised capital].

The board of directors may increasethe share capital by contributions in cash or in kind, by capitalisation of reserves, whether available or unavailable for distribution,and capitalisation of issue premiums, with or without the issuance of new shares, with or without voting rights, that will have the rightsas will be determined by the board of directors. The board of directors is also authorised to use this authorisation for the issuanceof convertible bonds or subscription rights, bonds with subscription rights or other securities.

This authorisation is validfor a period of five years as from the date of publication in the Annexes to the Belgian Official Gazette of an extract of the minutesof the extraordinary general shareholders’ meeting of the company held on [date of the general shareholders’ meeting approvingthe authorised capital].

In the event of a capital increasedecided by the board of directors within the framework of the authorised capital, all issue premiums booked, if any, will be accountedfor in accordance with the provisions of these articles of association.

The board of directors is authorised,when exercising its powers within the framework of the authorised capital, to restrict or cancel, in the interest of the company, thepreferential subscription rights of the shareholders. This restriction or cancellation of the preferential subscription rights can alsobe done in favour of members of the personnel of the company or of its subsidiaries, or in favour of one or more persons other than membersof the personnel of the company or of its subsidiaries.

The board of directors is authorised,with the right of substitution, to amend the articles of association, after each capital increase that has occurred within the frameworkof the authorised capital, in order to bring them in conformity with the new situation of the share capital and the shares.”

Quorum: As this extraordinary general shareholders’ meeting constitutes the second extraordinary general shareholders’ meeting for the aforementioned agenda items, no quorum is required for the deliberation and voting on the items referred to in the aforementioned agenda.

Voting and majority: Subject to applicable legal provisions, each share shall have one vote. In accordance with applicable law, the proposed resolutions referred to in the aforementioned agenda of the extraordinary general shareholders’ meeting shall be passed if they are approved by a majority of 75% of the votes validly cast by the shareholders. Pursuant to article 7:135 of the Belgian Companies and Associations Code, the holders of subscription rights have the right to participate to the extraordinary general shareholders’ meeting, but only with an advisory vote.

UnofficialEnglish translation – For informational purposes only

PARTICIPATION TO THE MEETING

Introduction: Holders of securities issued by the Company who wish to participate to the extraordinary general shareholders’ meeting of the Company should take into account the formalities and procedures described below.

Registration date: The registration date for the extraordinary general shareholders’ meeting shall be Friday 16 June 2023, at midnight (12:00 a.m., Belgian time). Only persons owning securities issued by the Company on Friday 16 June 2023, at midnight (12:00 a.m., Belgian time) shall be entitled to participate to, and, as the case may be, vote at the extraordinary general shareholders’ meeting. Only shareholders are entitled to vote. The holders of subscription rights can participate to the extraordinary general shareholders’ meeting but only with an advisory vote. Shareholders, as well as holders of subscription rights must satisfy the formalities that are described under “—Participation to the meeting”.

Participation to the meeting: In order to be able to participate to the extraordinary general meeting, a holder of securities issued by the Company must satisfy two conditions: (a) be registered as holder of such securities on the registration date, and (b) notify the Company, as described below:

(a)	Registration: Firstly, the right for a holder of securities issued by the<br>Company to participate to and, as applicable, to vote at the extraordinary general shareholders’ meeting is only granted on the<br>basis of the registration of the securities concerned on the aforementioned registration date at midnight, via registration, in the applicable<br>register book for the securities concerned (for registered securities) or in the accounts of a certified account holder or relevant settlement<br>institution for the securities concerned (for dematerialised shares).
(b)	Notification: Secondly, in order to participate to the extraordinary general<br>shareholders’ meeting, the holders of securities issued by the Company must notify the Company whether they want to participate<br>to the meeting and must do so prior to or at the latest on Saturday, 24 June 2023. The holders of securities who wish to make such notification<br>can make use of the attendance form that can be obtained at the Company’s registered office and on the Company’s website (http://www.mdxhealth.com).<br>The notice must reach the Company by mail at its registered office (MDxHealth SA, CAP Business Center, Zone Industrielle des Hauts-Sarts,<br>rue d’Abhooz 31, 4040 Herstal, Belgium, Attention: Mr. Ron Kalfus) or by e-mail at agsm@mdxhealth.com, at the latest on the sixth<br>calendar day prior to the extraordinary general shareholders’ meeting, i.e., on or before Saturday, 24 June 2023 at the latest.<br>For the holders of dematerialised securities, the notification should include a certificate confirming the number of securities that have<br>been registered in their name on the registration date. The certificate can be obtained by the holders of the dematerialised securities<br>with the certified account holder, the applicable settlement institution, or the relevant financial intermediary for the securities concerned.
---	---

(a)

Registration: Firstly, the right for a holder of securities issued by the Company to participate to and, as applicable, to vote at the extraordinary general shareholders’ meeting is only granted on the basis of the registration of the securities concerned on the aforementioned registration date at midnight, via registration, in the applicable register book for the securities concerned (for registered securities) or in the accounts of a certified account holder or relevant settlement institution for the securities concerned (for dematerialised shares).

(b)

Notification: Secondly, in order to participate to the extraordinary general shareholders’ meeting, the holders of securities issued by the Company must notify the Company whether they want to participate to the meeting and must do so prior to or at the latest on Saturday, 24 June 2023. The holders of securities who wish to make such notification can make use of the attendance form that can be obtained at the Company’s registered office and on the Company’s website (http://www.mdxhealth.com). The notice must reach the Company by mail at its registered office (MDxHealth SA, CAP Business Center, Zone Industrielle des Hauts-Sarts, rue d’Abhooz 31, 4040 Herstal, Belgium, Attention: Mr. Ron Kalfus) or by e-mail at agsm@mdxhealth.com, at the latest on the sixth calendar day prior to the extraordinary general shareholders’ meeting, i.e., on or before Saturday, 24 June 2023 at the latest. For the holders of dematerialised securities, the notification should include a certificate confirming the number of securities that have been registered in their name on the registration date. The certificate can be obtained by the holders of the dematerialised securities with the certified account holder, the applicable settlement institution, or the relevant financial intermediary for the securities concerned.

---

Voting by mail: The shareholders can vote by mail in accordance with article 39 of the Company’s articles of association. Votes by mail must be cast by means of the form prepared by the Company. The voting by mail form can be obtained on the Company’s website (http://www.mdxhealth.com). The voting by mail form must be signed in writing or electronically. The electronic signature must be a qualified electronic signature in the sense of Regulation (EU) No 910/2014 of the European Parliament and of the Council of 23 July 2014 on electronic identification and trust services for electronic transactions in the internal market and repealing Directive 1999/93/EC, as amended. Signed voting by mail forms must reach the Company by mail at its registered office (MDxHealth SA, CAP Business Center, Zone Industrielle des Hauts-Sarts, rue d’Abhooz 31, 4040 Herstal, Belgium, Attention: Mr. Ron Kalfus), or by e-mail at agsm@mdxhealth.com, at the latest on the sixth calendar day prior to the extraordinary general shareholders’ meeting, i.e., on or before Saturday, 24 June 2023 at the latest. Holders of securities who wish to vote by mail must in any case comply with the formalities to participate to the meeting as explained under “—Participation to the meeting”.

Representation by proxy: The holders of securities can participate to the meeting and vote, as applicable, through a written proxy, as the case may be, to the chair of the board of directors. Written proxy must contain specific voting instructions for each proposed resolution. Proxy forms can be obtained on the Company’s website (http://www.mdxhealth.com). The proxy must be signed in writing or electronically. The electronic signature must meet the same requirements as the electronic signature for the voting by mail form (see also “— Voting by mail”). Signed proxies must reach the Company by mail at its registered office (MDxHealth SA, CAP

UnofficialEnglish translation – For informational purposes only

Business Center, Zone Industrielle des Hauts-Sarts, rue d’Abhooz 31, 4040 Herstal, Belgium, Attention: Mr. Ron Kalfus) or by e-mail at agsm@mdxhealth.com, at the latest on the sixth calendar day prior to the extraordinary general shareholders’ meeting, i.e., on or before Saturday, 24 June 2023 at the latest. The appointment of a proxy holder must be made in accordance with the applicable rules of Belgian law, including in relation to conflicts of interests and the keeping of a register. Holders of securities who wish to be represented by proxy must, in any case comply with the formalities to participate to the meeting, as explained under “— Participation to the meeting”.

Right to ask questions: Each holder of securities issued by the Company has the right to ask questions to the directors and the statutory auditor related to items on the agenda of a general shareholders’ meeting. Questions can be asked during the meeting or can be submitted in writing prior to the meeting. Written questions must reach the Company by mail at its registered office (CAP Business Center, Zone Industrielle des Hauts-Sarts, rue d’Abhooz 31, 4040 Herstal, Belgium, Attention: Mr. Ron Kalfus) or by e-mail at agsm@mdxhealth.com at the latest on the sixth calendar day prior to the extraordinary general shareholders’ meeting, i.e., on or before Saturday, 24 June 2023 at the latest. Answers to written questions will be provided in writing and will be published on the Company’s website (http://www.mdxhealth.com) on or before Friday, 30 June 2023 at the latest, but before the vote on items on the agenda of the meeting concerned in accordance with applicable law. Oral questions will be answered during the meeting concerned in accordance with applicable law. In addition, in order for written questions to be considered, the holders of securities issued by the Company who submitted the written questions concerned must comply with the formalities to participate to the meeting, as explained under “—Participation to the meeting” and/or under “—Voting by mail” or “—Representation by proxy”.

Access to the meeting room: The natural persons who attend the extraordinary general shareholders’ meeting in their capacity as owner of securities, holder of proxies or representative of a legal entity must be able to provide evidence of their identity in order to be granted access to the meeting room (subject to what is shared above under “—General information”). In addition, the representatives of legal entities must hand over the documents establishing their capacity as corporate representative or attorney-in-fact. These documents will be verified immediately before the start of the meeting.

Recommendation to use e-mail: The deadline for the submission of this notification to attend the meeting, as well as voting by mail forms, proxy forms and written questions is on a Saturday, during which there is usually no ordinary postal service. Therefore, the Company recommends the holders of its securities to use e-mail for all communication with the Company regarding the general shareholders’ meeting. The Company’s e-mail address for such communication is: agsm@mdxhealth.com. The Company also points at that, in addition to be physically available at the Company’s registered office and distributed by mail, all forms and other documentation in relation to the general shareholders’ meeting will be available on the Company’s website (http://www.mdxhealth.com). See also “—Available documentation”.

DATA PROTECTION

The Company is responsible for the processing of personal data it receives from, or collects about, holders of securities issued by the Company and proxy holders in the context of general shareholders’ meeting. The processing of such data will be carried out for the purposes of the organisation and conduct of the relevant general shareholders’ meeting, including the convening notices, registrations, participation and voting, as well as for maintaining lists or registers of security holders, and the analysis of the investor and security holder base of the Company. The data include, amongst others, identification data, the number and nature of securities of a holder of securities issued by the Company, proxies and voting instructions. This data may also be transferred to third parties for the purposes of assistance or services to the Company in connection with the foregoing. The processing of such data will be carried out, mutatis mutandis, in accordance with the Company’s Privacy Policy, available on the Company’s website (https://mdxhealth.com/privacy-policy). The Company draws the attention of the holders of securities issued by the Company and proxy holders to the description of the rights they may have as data subjects, such as, among others, the right to access, the right to rectify and the right to object to processing, which are outlined in the aforementioned Privacy Policy. All this does not affect the rules that apply in connection with the registration and participation to the general shareholders’ meeting. To exercise rights as a data subject and for all other information regarding the processing of personal data by or on behalf of the Company, the Company can be contacted by e-mail at dataprotection@mdxhealth.com.

Unofficial Englishtranslation – For informational purposes only

AVAILABLE DOCUMENTATION

The following documentation is available on the Company’s website (http://www.mdxhealth.com): the notice convening the extraordinary general shareholders’ meeting, updates of the agenda and proposed resolutions, in case of amendments to the agenda and proposed resolutions, the documents to be submitted to the extraordinary general shareholders’ meeting as referred to in the agenda of the meeting, the attendance form, the voting by mail form, and the proxy form. Prior to the extraordinary general shareholders’ meeting, holders of securities of the Company can also obtain at the registered office of the Company (CAP Business Center, Zone Industrielle des Hauts-Sarts, rue d’Abhooz 31, 4040 Herstal, Belgium), free of cost, a copy of this documentation. The aforementioned website also mentions the total number of outstanding shares and voting rights of the Company.

Please address any correspondence on this matter to MDxHealth SA, Mr. Ron Kalfus CAP Business Center, Zone Industrielle des Hauts-Sarts, rue d’Abhooz 31, 4040 Herstal, Belgium. The facsimile number is +32 (0)4 259 78 75 and the e-mail address is agsm@mdxhealth.com.

On behalf of the board of directors

THIS DOCUMENT IS NOT AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY SHARES OR OTHER SECURITIES OF MDXHEALTH SA.

Exhibit 99.2

MDxHealth SA

Limited Liability Company(société anonyme)

CAP Business Center

Zone Industrielle des Hauts-Sarts

Rue d’Abhooz 31

4040 Herstal, Belgium

VAT BE 0479.292.440 (RLP Liège, division Liège)

ATTENDANCE FORM FOR SECURITY HOLDERS<br><br> <br>Extraordinary General Meeting**** to be held on Friday, 30 June 2023, at 9:00 a.m. (Belgian time)
This attendance form should be used by holders<br> of securities of MDxHealth SA (the “Company”) who want to attend the extraordinary general shareholders’ meeting in person.<br> More information regarding the requirements for, and the modalities of, participation in the meeting can be found in the convening notice<br> of the extraordinary general shareholders’ meeting.<br><br> <br><br><br> <br>The signed and completed form must reach the Company<br> at the latest on the sixth calendar day prior to the extraordinary general shareholders’ meeting, i.e., on or before Saturday, 24 June 2023 at the latest, by mail to:<br><br> <br><br><br> <br>MDxHealth SA<br><br> Attention Mr. Ron Kalfus<br><br> Company Secretary<br><br> <br>CAP Business Center<br><br> <br>Zone Industrielle des Hauts-Sarts<br><br> Rue d’Abhooz, 31<br><br> 4040 Herstal,<br><br> Belgium<br><br> <br>or by e-mail to:<br><br> <br><br><br> <br>agsm@mdxhealth.com<br><br> <br><br><br> <br>The deadline<br> for the submission of this notification to attend the meeting is on a Saturday, during which there is usually no ordinary postal service.<br> Therefore, the use of e-mail is strongly encouraged.<br><br> <br><br><br> <br>Holders of dematerialised<br> securities must attach to the present form a certificate issued by the certified account holder, the applicable settlement institution,<br> or the relevant financial intermediary for the securities concerned, confirming the number of securities that have been registered in<br> their name on the registration date (i.e., Friday, 16 June 2023, at midnight (12:00 a.m., Belgian time)), with which they want<br> to participate to the extraordinary general shareholders’ meeting.
---

ATTENDANCE FORM FOR SECURITY HOLDERS Extraordinary General Meeting**** to be held on Friday, 30 June 2023, at 9:00 a.m. (Belgian time)

This attendance form should be used by holders of securities of MDxHealth SA (the “Company”) who want to attend the extraordinary general shareholders’ meeting in person. More information regarding the requirements for, and the modalities of, participation in the meeting can be found in the convening notice of the extraordinary general shareholders’ meeting. The signed and completed form must reach the Company at the latest on the sixth calendar day prior to the extraordinary general shareholders’ meeting, i.e., on or before Saturday, 24 June 2023 at the latest, by mail to: MDxHealth SA Attention Mr. Ron Kalfus Company Secretary CAP Business Center Zone Industrielle des Hauts-Sarts Rue d’Abhooz, 31 4040 Herstal, Belgium or by e-mail to: agsm@mdxhealth.com The deadline for the submission of this notification to attend the meeting is on a Saturday, during which there is usually no ordinary postal service. Therefore, the use of e-mail is strongly encouraged. Holders of dematerialised securities must attach to the present form a certificate issued by the certified account holder, the applicable settlement institution, or the relevant financial intermediary for the securities concerned, confirming the number of securities that have been registered in their name on the registration date (i.e., Friday, 16 June 2023, at midnight (12:00 a.m., Belgian time)), with which they want to participate to the extraordinary general shareholders’ meeting.

---

Extraordinary General Shareholders' Meeting of MDxHealth SA - Attendance form for security holders

The undersigned,

First Name:	…………………………………………………………………
Family Name:	…………………………………………………………………
Address:	…………………………………………………………………
or
Corporate name:	…………………………………………………………………
Corporate form:	…………………………………………………………………
Registered office:	…………………………………………………………………<br><br> <br><br><br> <br>…………………………………………………………………
Represented by (first name, family name and capacity):	…………………………………………………………………<br><br> <br><br><br> <br>…………………………………………………………………<br><br> <br><br><br> <br>…………………………………………………………………<br><br> <br><br><br> <br>…………………………………………………………………

owner of the following number of securities issued by MDxHealth SA, with registered office at CAP Business Center, Zone Industrielle des Hauts-Sarts, rue d’Abhooz 31, 4040 Herstal, Belgium:

………………………………………………………………….<br><br> <br><br><br> <br>(Number of shares)
………………………………………………………………….<br><br> <br><br><br> <br>(Number of subscription rights)^(1)^
Note:
(1)	Pursuant to article 7:135 of the Belgian Companies and Associations Code, the holders of subscription rights have the right to attend the shareholders’ meeting, but only with an advisory vote.

Hereby notifies his/her/its intent to attend the extraordinary general shareholders’ meeting of MDxhealth SA to be held on Friday, 30 June 2023, at 9:00 a.m. (Belgian time) at the offices of the notary public Stijn Raes, at Kortrijksesteenweg 1147, 9051 Ghent, Belgium, or at such other place indicated at that place at that time.

The undersigned agrees that the English translation of the present attendance form is a free translation and for information purposes only, and that the French version shall prevail over the English translation.

The undersigned hereby confirms that the Company can send all confirmations and information required for participation in the extraordinary general shareholders’ meeting to the following e-mail address of the undersigned:

………………………………………………………………….<br><br> <br><br><br> <br>(E-mail address of security holder)

Extraordinary General Shareholders' Meeting of MDxHealth SA - Attendance form for security holders

Done at ……………………………………., on ………………………………2023

Signature……………………………

Extraordinary General Shareholders' Meeting of MDxHealth SA - Attendanceform for security holders

Exhibit 99.3

AssemblÉe gÉnÉrale extraordinaire des Actionnaires<br><br> <br>30 Juin 2023	extraordinary general shareholders’ meeting 30 June 2023
Procuration	Proxy
Cette<br> procuration doit être utilisée par les titulaires de titres de MDxHealth SA (la “Société”)<br> qui désirent être représentés par un mandataire spécial à l’assemblée générale<br> extraordinaire des actionnaires de la Société à tenir le vendredi 30 juin 2023 à 9h00 (heure belge).<br><br> <br><br><br> <br>Cette<br>procuration ne constitue pas une demande de procuration au sens des articles 7:144 et 7:145 du Code des sociétés et des<br>associations.<br><br> <br><br><br> <br>La<br> procuration doit être signée de façon écrite ou électroniquement. Si une signature électronique<br> est utilisée, elle doit être une signature électronique qualifiée au sens du Règlement (UE) n°<br> 910/2014 du Parlement européen et du Conseil du 23 juillet 2014 sur l’identification électronique et les services de<br> confiance pour les transactions électroniques au sein du marché intérieur et abrogeant la directive 1999/93/CE,<br> tel que modifié.<br><br> <br><br><br> <br>La<br> procuration signée et complétée doit parvenir à la Société au plus tard le sixième<br> jour calendrier qui précède l’assemblée générale extraordinaire des actionnaires, soit le, ou avant le, samedi 24 juin 2023 au plus tard. Jusqu’à cette date, les procurations peuvent être envoyées<br> à l’adresse suivante :<br><br> <br><br><br> <br>MDxHealth<br> SA<br><br> A l’attention de M. Ron Kalfus<br><br> Secrétaire de la Société<br><br> CAP Business Center<br><br> <br>Zone<br> Industrielle des Hauts-Sarts<br><br> <br>Rue<br> d’Abhooz 31,<br><br> 4040 Herstal<br><br> <br>Belgique<br><br> <br><br><br> <br>ou<br> par courrier électronique à :<br><br> <br>agsm@mdxhealth.com	This<br> proxy should be used by holders of securities of MDxHealth SA (the “Company”) who want to be represented by a proxy<br> holder at the extraordinary general shareholders’ meeting of the Company to be held on Friday, 30 June 2023, at 9:00 a.m. (Belgian<br> time).<br><br> <br><br><br> <br>This<br>proxy does not constitute a proxy solicitation in the sense of articles 7:144 and 7:145 of the Belgian Companies and Associations Code.<br><br> <br><br><br> <br>The<br>proxy must be signed in writing or electronically. In the event an electronic signature is used, it must be a qualified electronic signature<br>in the sense of Regulation (EU) No 910/2014 of the European Parliament and of the Council of 23 July 2014 on electronic identification<br>and trust services for electronic transactions in the internal market and repealing Directive 1999/93/EC, as amended.<br><br> <br><br><br> <br>The<br> signed and completed proxy must reach the Company at the latest on the sixth calendar day prior to the extraordinary general shareholders’<br> meeting, i.e. on or before Saturday, 24 June 2023 at the latest. Until this date, proxies can be sent to the following<br> address:<br><br> <br><br><br> <br>MDxHealth<br> SA<br><br> Attention Mr. Ron Kalfus<br><br> Company Secretary<br><br> <br>CAP<br> Business Center<br><br> <br>Zone<br> Industrielle des Hauts-Sarts<br><br> Rue d’Abhooz, 31<br><br> 4040 Herstal,<br><br> Belgium<br><br> <br><br><br> <br>or<br> by e-mail to:<br><br> <br>agsm@mdxhealth.com
Les<br> titulaires de titres de la Société qui désirent être représentés par procuration doivent<br> aussi s’enregistrer à l’assemblée générale extraordinaire des actionnaires, tel que décrit dans<br> l’invitation à l’assemblée générale extraordinaire des actionnaires. Les titulaires de titres dématérialisés<br> doivent joindre à ce formulaire un certificat délivré par le teneur de compte agréé, l’organisme<br> de liquidation compétent, ou de l’intermédiaire financier pour les titres concernés, confirmant le nombre de<br> titres ayant été enregistrés à leur nom à la date d’enregistrement (soit le vendredi 16 juin 2023,<br> à minuit (00h00, heure belge)) et avec lesquelles ils veulent participer à l’assemblée générale<br> extraordinaire des actionnaires.	Holders<br> of securities of the Company who wish to be represented by proxy must also register for the extraordinary general shareholders’ meeting,<br> as described in the notice convening the extraordinary general shareholders’ meeting. Holders of dematerialised securities must attach<br> to the present form a certificate issued by the certified account holder, the applicable settlement institution, or the relevant<br> financial intermediary for the securities concerned, confirming the number of securities that have been registered in their name<br> on the registration date, (i.e., Friday, 16 June 2023, at midnight (12:00 a.m., Belgian time)) with which they want to participate<br> to the extraordinary general shareholders’ meeting.
La<br> date limite pour la communication de cette procuration est un samedi, pendant laquelle il n’y a généralement pas de<br> service postal ordinaire. Ainsi, la Société recommande d’utiliser le courrier électronique pour toute communication<br> avec la Société concernant l’assemblée générale d’actionnaires.	The<br> deadline for the submission of this proxy form is on a Saturday, during which there is usually no ordinary postal service. Therefore,<br> the Company recommends to use e-mail for all communication with the Company regarding the general shareholders’ meeting.
Assemblée Générale Extraordinaire des Actionnaires de MDxHealth SA - Procuration
---	---
Extraordinary General Shareholders’ Meeting of MDxHealth SA - Proxy	1/10
Le/La soussigné(e),	The undersigned,
---	---
Prénom / First name:	...........................................................................................................................................
---	---
Nom de famille / Family name:	...........................................................................................................................................
Adresse / Address:	...........................................................................................................................................
ou / or
Dénomination / Corporate name:	...........................................................................................................................................
Forme juridique / Corporate form:	...........................................................................................................................................
Siège / Registered office:	...........................................................................................................................................
	...........................................................................................................................................
Représenté par (prénom, nom de famille et	...........................................................................................................................................
qualité) / Represented by (first name, family	...........................................................................................................................................
name and capacity):	...........................................................................................................................................
titulaire du (des) nombre(s) suivant(s) de titres émis par MDxHealth SA, ayant son siège au CAP Business Center, Zone Industrielle des Hauts-Sarts, Rue d’Abhooz 31, 4040 Herstal, Belgique,	owner of the following number of securities issued by MDxHealth SA, with its registered office at CAP Business Center, Zone Industrielle des Hauts-Sarts, rue d’Abhooz 31, 4040 Herstal, Belgium,
---	---
Nombre d’actions / Number of shares:	………………..
---	---
Forme des actions susmentionnées / Form of the above mentioned shares:<br><br><br><br>(veuillez cocher la case appropriée / please tick the appropriate box)
☐ Nominatives / Registered<br> ☐ Dématérialisées / Dematerialised
Nombre de droits de souscription / Number of subscription rights:^1^	………………..
constitue<br>pour mandataire spécial, avec pouvoir de substitution:	appoints<br>as his/her/its proxy holder, with power of substitution:
---	---

☐ M./Mme / Mr./Ms. …………………………………………………………………………………………^2^

☐ Président du conseil d’administration / Chair of the board of directors^3^

^1^Conformément à l’article 7:135 du Code des sociétés et des associations, les titulaires de droits de souscription ont le droit de participer à l’assemblée générale des actionnaires mais seulement avec voix consultative.<br><br> <br><br><br> <br>^2^Veuillez compléter tel qu’approprié. Une absence d’instruction sera interprétée comme une nomination du président du conseil d’administration en tant que mandataire.	^1^Pursuant to article 7:135 of the Belgian Companies and Associations Code, the holders of subscription rights have the right to attend the shareholders’ meeting, but only with an advisory vote.<br><br> <br><br><br> <br>^2^Please complete as appropriate. An absence of instruction shall be tantamount to an appointment of the chair of the board of directors as proxy holder.
^3^Le président du conseil d’administration de la Société a le pouvoir de nommer un autre administrateur, un employé ou remplaçant désigné de la Société comme suppléant en vertu d’une sous-délégation si le président est empêché d’assister à l’assemblée générale des actionnaires. Veuillez noter que le président du conseil d’administration de la Société ou, le cas échéant, son suppléant, est un administrateur, un employé ou un remplaçant désigné de la Société et a donc un conflit d’intérêts potentiel tel que défini dans l’article 7:143, §4 du Code des sociétés et des associations. Le président ou son suppléant ne vote qu’en exécution de la procuration, conformément aux instructions de vote spécifiques figurant dans la procuration. Voir également la note 2 ci-dessous.	^3^The chair of the board of directors of the Company has the power to appoint another director, employee or substitute of the Company as a substitute pursuant to a sub delegation if the chair is hindered to attend the general shareholders’ meeting. Please note that the chair of the board of directors of the Company or, as the case may be, his substitute, is a director, employee or substitute of the Company and therefore has a potential conflict of interest as defined in article 7:143, §4 of the Belgian Companies and Associations Code. The chair or his substitute may only vote in execution of the proxy, in accordance with the specific voting instructions included in the proxy. See also note 2 below.
Assemblée Générale Extraordinaire des Actionnaires de MDxHealth SA - Procuration
---	---
Extraordinary General Shareholders’ Meeting of MDxHealth SA - Proxy	2/10
lequel accepte ainsi d’être nommé, et à qui le/la soussigné(e) donne les pouvoirs et instructions de vote spécifiques suivants:^4^	who agrees to be so appointed, and to whom the undersigned gives the following powers and specific voting instructions:^4^
---	---
^4^Veuillez indiquer l’instructionde vote dans les cases appropriées pour les points à l’ordre du jour. En l’absence d’une instructionde vote pour un point de l’ordre du jour, ou dans le cas où, pour quelque raison que ce soit, il y aurait un manque de clartéconcernant les instructions de vote, le mandataire sera présumé avoir voté “en faveur” des résolutionsproposées soutenues par le conseil d’administration et cela sera considéré comme une instruction de vote spécifiqueau sens de l’article 7:143 §4 2° du Code des sociétés et des associations.	^4^Please indicate the voting instructions in the appropriate boxes of the agenda items. In the absence of voting instructions for any agenda item or in the event that, for any reason whatsoever, any uncertainty would arise with regards to the voting instructions, the proxy holder will be presumed to have voted “in favour” of the proposed resolutions supported by the board of directors and that this will be deemed to be a specific voting instruction in the sense of article 7:143 §4 2° of the Belgian Companies and Associations Code.
I. De représenter le/la soussigné(e) à l’assemblée générale extraordinaire des actionnaires<br> à tenir le vendredi 30 juin 2023 à 9h00 (heure belge), dans les bureaux de Maître Stijn Raes, notaire, à Kortrijksesteenweg<br> 1147, 9051 Gand, Belgique, ou à tout autre endroit qui sera indiqué à cette occasion.	I. To represent the undersigned at the extraordinary general meeting of shareholders to be held on Friday, 30 June 2023 at 9:00<br> a.m. (Belgian time), at the offices of the notary public Stijn Raes, at Kortrijksesteenweg 1147, 9051 Ghent, Belgium, or at such place<br> as will be indicated at that place at that time.
Assemblée Générale Extraordinaire des Actionnaires de MDxHealth SA - Procuration
---	---
Extraordinary General Shareholders’ Meeting of MDxHealth SA - Proxy	3/10
ORDRE DU JOUR<br><br> <br>assemblée générale extraordinaire	agenda<br><br> <br>extraordinary general meeting
---	---
1.	Communication des rapports - Plan d’Option sur Action de 2023	1.	Submission of reports - 2023 Share Option Plan
---	---	---	---
	Communication des, discussion sur:		Submission of, discussion on:
	a) le rapport du conseil d’administration de la Société conformément aux articles 7:180 et 7:191 du Code des sociétés et associations relatif à la proposition d’émettre 5.000.000 nouveaux droits de souscription de la Société (les “2023 Share Options”), en vertu d’un plan d’option sur action dénommé “le Plan d’Option sur Action de 2023”, et de supprimer, dans l’intérêt de la Société, le droit de préférence des actionnaires existants de la Société et, pour autant que de besoin, des détenteurs de droits de souscription en circulation (share options) ou American Depositary Shares (“ADSs”) de la Société, en faveur des membres du personnel de la Société et de ses filiales de temps à autre, au sens de l’article 1:27 du Code des sociétés et des associations (les “Participants Sélectionnés”); et		a) the report of the board of directors of the Company in accordance with articles 7:180 and 7:191 of the Belgian Companies and Associations Code in relation to the proposal to issue 5,000,000 new subscription rights for shares of the Company (the “2023 Share Options”), pursuant to a share option plan named “the 2023 Share Option Plan”, and to dis-apply, in the interest of the Company, the preferential subscription right of the existing shareholders of the Company and, insofar as required, of the holders of outstanding subscription rights (share options) or American Depositary Shares (“ADSs”) of the Company, for the benefit of the members of the personnel of the Company and its subsidiaries from time to time, within the meaning of article 1:27 of the Belgian Companies and Associations Code (the “Selected Participant”); and
	b) le rapport du commissaire de la Société conformément aux articles 7:180 et 7:191 du Code des sociétés et des associations concernant la proposition d’émettre 5.000.000 2023 Share Options et de supprimer, dans l’intérêt de la Société, le droit de préférence des actionnaires existants de la Société et, pour autant que de besoin, des détenteurs de droits de souscription en circulation (share options) ou ADSs de la Société, en faveur des Participant Sélectionnés.		b) the report of the statutory auditor of the Company in accordance with articles 7:180 and 7:191 of the Belgian Companies and Associations Code in relation to the proposal to issue 5,000,000 2023 Share Options, and to dis-apply, in the interest of the Company, the preferential subscription right of the existing shareholders of the Company and, insofar as required, of the holders of outstanding subscription rights (share options) or ADSs of the Company, to the benefit of the Selected Participants.
2.	Proposition d’émettre<br>5.000.000 2023 Share Options	2.	Proposal to issue 5,000,000 2023 Share Options
►	Proposition de résolution:	►	Proposed resolution:
	L’assemblée<br>générale des actionnaires décide d’approuver l’émission de 5.000.000 2023 Share Options, en vertu d’un plan<br>d’option sur action dénommé “le Plan d’Option sur Action de 2023”, et de supprimer, dans l’intérêt<br>de la Société, le droit de préférence des actionnaires existants de la Société et, pour autant<br>que de besoin, des détenteurs de droits de souscription en circulation (share options) ou ADSs de la Société,<br>en faveur des Participants Sélectionnés. En conséquence, le conseil d’administration décide de ce qui suit:		The general shareholders’<br>meeting resolves to approve the issuance of 5,000,000 2023 Share Options, pursuant to a share option plan named “the 2023 Share Option<br>Plan”, and to dis-apply, in the interest of the Company, the preferential subscription right of the existing shareholders of the<br>Company and, insofar as required, of the holders of outstanding subscription rights (share options) or ADSs of the Company, for the benefit<br>of Selected Participant. In view thereof, the general shareholders’ meeting resolves as follows:
	(a) Termes et conditions<br>des 2023 Share Options: Les termes et conditions des 2023 Share Options (inclus, mais sans s’y limiter, le prix d’exercice des 2023<br>Share Options) seront tels que figurant dans l’annexe au rapport du conseil d’administration visé au point 1.(a) de l’ordre du<br>jour (aux fins de la présente résolution, le “Plan”), dont une copie restera jointe au présent procès-verbal.<br>Les 2023 Share Options ont une durée de 10 ans à partir de leur date d’émission.		(a) Terms and conditions<br>of the 2023 Share Options: The terms and conditions of the 2023 Share Options (including, but not limited to, the exercise price of<br>the 2023 Share Options) shall be as set out in the annex to the report of the board of directors referred to in item 1.(a) of the agenda<br>(for the purpose of this resolution, the “Plan”), a copy of which shall remain attached to the minutes reflecting the<br>present resolution. The 2023 Share Options have a term of ten years as from their issue date.
	(b) Actions sous-jacentes:<br>Chaque 2023 Share Option donne à son détenteur le droit de souscrire à une nouvelle action qui sera émise<br>par la Société. Les nouvelles actions à émettre lors de l’exercice des 2023 Share Options auront les mêmes<br>droits et avantages, et seront à tous égards pari passu, en ce compris en ce qui concerne les droits aux dividendes<br>et autres distributions, avec les actions existantes et en circulation de la Société au moment de leur émission,<br>et auront droit aux dividendes et autres distributions pour lesquelles la date d’enregistrement ou la date d’échéance tombe<br>à, ou après la date d’émission des actions.		(b) Underlying shares:<br>Each 2023 Share Option shall entitle the holder thereof to subscribe for one new share to be issued by the Company. The new shares to<br>be issued at the occasion of the exercise of the 2023 Share Options shall have the same rights and benefits as, and rank pari passu<br>in all respects, including as to entitlements to dividends and other distributions, with the existing and outstanding shares of the Company<br>at the moment of their issuance, and will be entitled to dividends and other distributions in respect of which the relevant record date<br>or due date falls on or after the date of issue of the shares.
Assemblée Générale Extraordinaire des Actionnaires de MDxHealth SA - Procuration
---	---
Extraordinary General Shareholders’ Meeting of MDxHealth SA - Proxy	4/10
(c) Suppression du droit<br>de préférence en faveur des Participants Sélectionnés: L’assemblée générale des actionnaires<br>décide, conformément à l’article 7:191 du Code des sociétés et des associations, de supprimer, dans<br>l’intérêt de la Société, le droit de préférence des actionnaires existants de la Société<br>et, pour autant que de besoin, des détenteurs de droits de souscription en circulation (share options) de la Société,<br>en faveur des Participants Sélectionnés, et d’approuver la possibilité pour la Société d’octroyer<br>les 2023 Share Options aux Participants Sélectionnés, comme expliqué plus en détail dans le rapport du conseil<br>d’administration visé au point 1.(a) de l’ordre du jour et dans les termes et conditions du Plan.	(c) Dis-application of the<br>preferential subscription right for the benefit of the Selected Participants: The general shareholders’ meeting resolves, in accordance<br>with article 7:191 of the Belgian Companies and Associations Code, to dis-apply, in the interest of the Company, the preferential subscription<br>right of the existing shareholders of the Company and, insofar as required, of the holders of outstanding subscription rights (share options)<br>or ADSs of the Company, for the benefit of the Selected Participants, and to approve the possibility for the Company to grant the 2023<br>Share Options to the Selected Participants, as further explained in the report of the board of directors referred to in item 1.(a) of<br>the agenda and the terms and conditions of the Plan.
---	---
(d) Confirmation de la souscription<br>de 2023 Share Options par la Société: L’assemblée générale des actionnaires décide d’approuver<br>et de confirmer que la Société sera en mesure de souscrire aux 2023 Share Options, en vue de créer un pool de 2023<br>Share Options disponible pour des octrois ultérieurs aux Participants Sélectionnés. La Société ne peut<br>cependant pas exercer les 2023 Share Options pour son compte propre.	(d) Confirmation of the<br>subscription of 2023 Share Options by the Company: The general shareholders’ meeting resolves to approve and confirm that the Company<br>will be able to subscribe for the 2023 Share Options, with a view to creating a pool of outstanding 2023 Share Options available for further<br>grants to Selected Participants. The Company may not, however, exercise the 2023 Share Options for its own account.
(e) Augmentation de capital<br>conditionnelle et émission de nouvelles actions: L’assemblée générale des actionnaires décide,<br>sous réserve et dans la mesure de l’exercice des 2023 Share Options, d’augmenter le capital de la Société et d’émettre<br>le nombre approprié de nouvelles actions pouvant être émises lors de l’exercice des 2023 Share Options. Sous réserve<br>et conformément aux dispositions du Plan, lors de l’exercice des 2023 Share Options et de l’émission de nouvelles actions,<br>le montant total du prix d’exercice des 2023 Share Options sera affecté au capital de la Société. Dans la mesure<br>où le montant du prix d’exercice des 2023 Share Options, par action à émettre lors de l’exercice des 2023 Share Options,<br>excède le pair comptable des actions de la Société existantes alors immédiatement avant l’émission<br>des nouvelles actions concernées, une partie du prix d’exercice, par action à émettre lors de l’exercice des 2023<br>Share Options, égale à ce pair comptable sera comptabilisée en capital, le solde étant comptabilisé<br>en prime d’émission. Suite à l’augmentation de capital et à l’émission de nouvelles actions, chaque action<br>nouvelle et existante représentera la même fraction du capital de la Société.	(e) Conditional capital<br>increase and issue of new shares: The general shareholders’ meeting resolves, subject to, and to the extent of the exercise of 2023<br>Share Options, to increase the Company’s share capital and to issue the relevant number of new shares issuable upon the exercise of the<br>2023 Share Options. Subject to, and in accordance with, the provisions of the Plan, upon exercise of the 2023 Share Options and issue<br>of new shares, the aggregate amount of the exercise price of the 2023 Share Options will be allocated to the share capital of the Company.<br>To the extent that the amount of the exercise price of the 2023 Share Options, per share to be issued upon exercise of the 2023 Share<br>Options, exceeds the fractional value of the then existing shares of the Company existing immediately prior to the issue of the new shares<br>concerned, a part of the exercise price, per share to be issued upon exercise of the 2023 Share Options, equal to such fractional value<br>shall be booked as share capital, whereby the balance shall be booked as issue premium. Following the capital increase and issuance of<br>new shares, each new and existing share shall represent the same fraction of the share capital of the Company.
Assemblée Générale Extraordinaire des Actionnaires de MDxHealth SA - Procuration
---	---
Extraordinary General Shareholders’ Meeting of MDxHealth SA - Proxy	5/10
(f) Prime d’émission:<br>Toute prime d’émission qui sera comptabilisée en relation avec les 2023 Share Options sera comptabilisée sur un compte<br>indisponible au passif du bilan de la Société dans ses capitaux propres, et le compte sur lequel la prime d’émission<br>sera comptabilisée constituera, au même titre que le capital de la Société, la garantie des tiers et, sauf<br>possibilité de capitalisation de ces réserves, ne pourra être réduit ou supprimé que par une décision<br>de l’assemblée générale des actionnaires statuant dans les conditions requises pour la modification des statuts de<br>la Société.	(f) Issue premium: Any<br>issue premium that will be booked in connection with the 2023 Share Options shall be accounted for on a non-distributable account on the<br>liabilities side of the Company’s balance sheet under its net equity, and the account on which the issue premium will be booked shall,<br>like the share capital, serve as a guarantee for third parties and can only be reduced on the basis of a lawful resolution of the general<br>shareholders’ meeting passed in the manner required for an amendments to the Company’s articles of association.
---	---
(g) Procurations: Le<br>conseil d’administration est autorisé à mettre en œuvre et à exécuter les décisions prises par<br>l’assemblée générale des actionnaires en rapport avec les 2023 Share Options, et à prendre toutes les mesures<br>et à accomplir toutes les formalités requises en vertu du Plan, des statuts de la Société et de la loi applicable<br>afin d’émettre ou transférer les actions lors de l’exercice des 2023 Share Options. En outre, chaque administrateur de la<br>Société, Joe Sollee et Ron Kalfus, chacun agissant individuellement et avec possibilité de subdélégation<br>et pouvoir de subrogation, auront le pouvoir, lors de l’exercice des 2023 Share Options, (i) de procéder à la constatation<br>(A) de l’augmentation de capital et de l’émission de nouvelles actions résultant de cet exercice, (B) de l’allocation du<br>capital et (le cas échéant) de la prime d’émission, et (C) de la modification des statuts de la Société<br>afin de refléter le nouveau capital et nombre d’actions en circulation suite à l’exercice des 2023 Share Options, (ii) de<br>signer et remettre, au nom de la Société, la documentation Euroclear, Euronext et bancaire pertinente, le registre des actions<br>et tous les documents nécessaires en relation avec l’émission et la livraison des actions au Participant Sélectionné,<br>et (iii) faire tout ce qui peut être nécessaire ou utile (y compris, mais sans s’y limiter, la préparation et l’exécution<br>de tous les documents et formulaires) pour l’admission des actions émises lors de l’exercice des 2023 Share Options à la<br>négociation sur le marché réglementé d’Euronext Brussels (ou tout autre marché sur lequel les actions<br>de la Société seront négociées à ce moment).	g) Powers of attorney:<br>The board of directors is authorised to implement and execute the resolutions passed by the general shareholders’ meeting in connection<br>with the 2023 Share Options, and to take all steps and carry out all formalities that shall be required by virtue of the Plan, the Company’s<br>articles of association and applicable law in order to issue or transfer the shares upon exercise of the 2023 Share Options. Furthermore,<br>each of the Company’s directors, Joe Sollee and Ron Kalfus, each such person acting individually and with possibility of sub-delegation<br>and the power of subrogation, shall have the power, upon exercise of the 2023 Share Options, (i) to proceed with the recording of (A)<br>the capital increase and issue of new shares resulting from such exercise, (B) the allocation of the share capital and (as applicable)<br>the issue premium, and (C) the amendment of the Company’s articles of association in order to reflect the new share capital and number<br>of outstanding shares following the exercise of the 2023 Share Options, (ii) to sign and deliver, on behalf of the Company, the relevant<br>Euroclear, Euronext and bank documentation, the share register and all necessary documents in connection with the issuance and delivery<br>of the shares to the beneficiary, and (iii) to do whatever may be necessary or useful (including but not limited to the preparation and<br>execution of all documents and forms) for the admission of the shares issued upon the exercise of the 2023 Share Options to trading on<br>the regulated market of Euronext Brussels (or such other markets on which the Company’s shares will be trading at that time).
(h) Renonciation: L’assemblée<br>générale des actionnaires reconnaît que les 2023 Share Options qui seront octroyés dans le cadre du “Plan<br>d’Option sur Action de 2023” ne seront pas considérées comme une “rémunération variable”, une<br>“rémunération fixe” ou une “rémunération annuelle” au sens du Code des sociétés<br>et associations (y compris, sans limitation, aux fins des articles 3:6, §3, 7:89/1, 7:90, 7:91, 7:92, 7:100, 7:108 et 7:121 du Code<br>des sociétés et associations) et du Code belge de gouvernance d’entreprise 2020 (y compris, sans limitation, aux fins de<br>la disposition 11 du Code belge de gouvernance d’entreprise 2020). L’assemblée générale des actionnaires approuve<br>les conditions et mécanismes d’acquisition définitive des 2023 Share Options, telles qu’elles sont inclues dans le Plan.<br>Les dispositions des articles 7:91, 7:108 et 7:121 (selon le cas) du Code des sociétés et associations sont expressément<br>écartées en ce qui concerne le Plan des 2023 Share Options.	(h) Waiver: The general<br>shareholders’ meeting acknowledges that the 2023 Share Options to be granted under the “2023 Share Option Plan” shall not be<br>considered “variable remuneration”, “fixed remuneration” or “annual remuneration” within the meaning of<br>the Belgian Companies and Associations Code (including, without limitation, for the purpose of articles 3:6, §3, 7:89/1, 7:90, 7:91,<br>7:92, 7:100, 7:108 and 7:121 of the Belgian Companies and Associations Code) and the 2020 Corporate Governance Code (including, without<br>limitation, for the purpose of provision 11 of the 2020 Corporate Governance Code). The general shareholders’ meeting approves the vesting<br>conditions and mechanisms of the 2023 Share Options, as included in the Plan. The provisions of articles 7:91, 7:108 and 7:121 (as applicable)<br>of the Belgian Companies and Associations Code are expressly dis-applied in relation to the 2023 Share Option Plan.
Assemblée Générale Extraordinaire des Actionnaires de MDxHealth SA - Procuration
---	---
Extraordinary General Shareholders’ Meeting of MDxHealth SA - Proxy	6/10
(i) Approbation conformément<br>à l’article 7:151 du Code des sociétés et des associations: L’assemblée générale des actionnaires<br>décide de prendre note, d’approuver et de ratifier, pour autant que de besoin conformément à l’article 7:151 du Code<br>des sociétés et des associations, toutes les clauses incluses dans le Plan, qui entrent en vigueur au moment où un<br>changement de contrôle se produit et qui tombent ou pourraient être considérées comme tombant sous le coup de<br>l’article 7:151 du Code des sociétés et associations (relatif à l’octroi de droits à des tiers affectant substantiellement<br>le patrimoine de la Société ou donnant naissance à une dette ou à un engagement substantiel à sa charge,<br>lorsque l’exercice de ces droits dépend du lancement d’une offre publique d’acquisition sur les actions de la Société<br>ou d’un changement du contrôle exercé sur), y compris, sans limitation, le mécanisme d’acquisition accélérée<br>automatique lors d’une acquisition tel que défini dans le Plan. L’assemblée générale des actionnaires accorde<br>une procuration spéciale à chaque administrateur de la Société, agissant seul et avec pouvoir de substitution,<br>aux fins d’accomplir les formalités requises par l’article 7:151 du Code des sociétés et des associations en ce qui<br>concerne la présente résolution.	(i) Approval in accordance<br>with article 7:151 of the Belgian Companies and Associations Code: The general shareholders’ meeting resolves to take note, approve<br>and ratify, insofar as required in accordance with article 7:151 of the Belgian Companies and Associations Code, all clauses included<br>in the Plan, which come into effect at the moment a change of control occurs and which fall or could be considered to fall within the<br>scope of article 7:151 of the Belgian Companies and Associations Code (relating to the granting of rights to third parties that substantially<br>affect the Company’s assets and liabilities, or give rise to a substantial debt or commitment on its behalf, when the exercise of these<br>rights is subject to the launching of a public takeover bid on the shares of the Company or to a change in the control exercised over<br>it), including, without limitation, the automatic accelerated vesting mechanism upon acquisition as defined in the Plan. The general shareholders’<br>meeting grants a special power of attorney to each director of the Company, acting alone and with power of substitution, for the purpose<br>of carrying out the formalities required by article 7:151 of the Belgian Companies and Associations Code with respect to this resolution.
---	---
► Instruction de vote:	► Voting instruction:
---	---
0 Pour / For	0 Contre / Against	0 Abstention
---	---	---
3. Communication<br> du rapport spécial du conseil d’administration conformément à l’article 7:199 du Code des sociétés<br> et des associations relatif à la proposition de renouveler le capital autorisé<br><br> <br><br><br> <br>Considération, discussion et<br> communication du rapport spécial du conseil d’administration conformément à l’article 7:199 du Code des sociétés<br> et des associations relatif à la proposition de renouveler les pouvoirs conférés au conseil d’administration dans<br> le cadre du capital autorisé, tel que repris ci-dessous au point 4 de l’ordre du jour de l’assemblée générale<br> extraordinaire des actionnaires, et exposant les circonstances spécifiques dans lesquelles le conseil d’administration pourra utiliser<br> ses pouvoirs dans le cadre du capital autorisé, et les objectifs qu’il devra poursuivre.<br><br> <br><br><br> <br><br><br> <br>4. Renouvellement<br> de l’autorisation au conseil d’administration d’augmenter le capital dans le cadre du capital autorisé<br><br> <br><br><br> <br>Afin de permettre au conseil d’administration<br> de disposer de la flexibilité nécessaire pour lever des fonds propres supplémentaires lorsque le besoin s’en fait<br> sentir ou qu’une opportunité se présente, le conseil d’administration propose de lui accorder des pouvoirs limités<br> dans le cadre du capital autorisé pour augmenter le capital de la Société d’un montant maximum égal à<br> 100% du montant du capital de la Société pendant une période de cinq (5) ans, le tout comme indiqué ci-dessous.<br> Pour de plus amples informations sur les circonstances dans lesquelles le conseil d’administration pourrait faire usage du capital autorisé<br> et sur les objectifs que le conseil d’administration poursuivrait avec le capital autorisé, voyez également le rapport spécial<br> mentionné au point 3 de l’ordre du jour de l’assemblée générale extraordinaire des actionnaires.	3. Submission<br> of the special report of the board of directors in accordance with article 7:199 of the Belgian Companies and Associations Code relating<br> to the proposal to renew the authorised capital<br><br> <br><br><br> <br>Consideration, discussion and submission<br> of the special report of the board of directors in accordance with article 7:199 of the Belgian Companies and Associations Code relating<br> to the proposal to renew the powers granted to the board of directors under the authorised capital, as set out below in item 4 of the<br> agenda of the extraordinary general shareholders’ meeting, and setting out the specific circumstances in which the board of directors<br> will be able to use its powers under the authorised capital, and the purposes that it should pursue.<br><br> <br><br><br> <br>4. Renewal<br> of the authorisation to the board of directors to increase the share capital within the framework of the authorised capital<br><br> <br><br><br> <br>In order to allow the board of directors<br> the flexibility to raise additional equity-based financing as and when the need may arise or an opportunity would present itself, the<br> board of directors proposes that it be granted limited powers under the authorised capital to increase the Company’s share capital by<br> a maximum amount of 100% during a term of five (5) years, all as further set out below. For further information on the circumstances in<br> which the board of directors could make use of the authorised capital and the objectives that the board of directors would pursue with<br> the authorised capital, see also the special report referred to in item 3 of the agenda of the extraordinary general shareholders’ meeting.
---	---
Assemblée Générale Extraordinaire des Actionnaires de MDxHealth SA - Procuration
---	---
Extraordinary General Shareholders’ Meeting of MDxHealth SA - Proxy	7/10
► Proposition de résolution:	► Proposed resolution:
---	---
L’assemblée<br> générale des actionnaires décide de renouveler l’autorisation donnée au conseil d’administration d’augmenter<br> le capital en une ou plusieurs fois, pendant une période de cinq (5) ans à compter de la publication aux Annexes du Moniteur<br> belge de la présente autorisation, d’un montant total jusqu’à 100% du montant du capital de la Société, et<br> ce conformément aux conditions et modalités fixées dans le rapport spécial du conseil d’administration établi<br> conformément à l’article 7:199 du Code des sociétés et des associations, tel que visé au point 3 de<br> l’ordre du jour de la présente assemblée générale extraordinaire des actionnaires. En conséquence,<br> l’assemblée générale des actionnaires décide de supprimer l’article 6 “Capital autorisé”<br> des statuts de la Société et de le remplacer par le texte suivant (la date mentionnée dans la sous-section entre<br> crochets étant la date de l’assemblée générale approuvant le capital autorisé renouvelé, et<br> le montant mentionné dans la sous-section entre crochets étant le montant du capital de la Société au moment<br> de l’assemblée générale approuvant le capital autorisé):<br><br> <br><br><br> <br>“Article 6 : Capital Autorisé<br><br> <br><br><br> <br>Le conseil d’administration est autorisé à augmenter le capital de la société en une ou plusieurs fois d’un montant total maximum de [100 % du capital de la société au moment de l’adoption du nouveau capital autorisé].<br><br> <br><br><br> <br>Le conseil d’administration peut augmenter le capital par des apports en numéraire ou en nature, par l’incorporation de réserves, disponibles ou non, et par l’incorporation de primes d’émission, avec ou sans émission de nouvelles actions, avec ou sans droit de vote, qui auront les droits qui seront déterminés par le conseil d’administration. Le conseil d’administration est également autorisé à utiliser cette autorisation pour l’émission d’obligations convertibles ou de droits de souscription, d’obligations avec droits de souscription ou d’autres titres.<br><br> <br><br><br> <br>Cette autorisation est valable pour une période de cinq ans à compter de la date de publication aux Annexes du Moniteur belge d’un extrait du procès-verbal de l’assemblée générale extraordinaire des actionnaires de la société tenue le [date de l’assemblée générale approuvant le capital autorisé renouvelé].<br><br> <br><br><br> <br>En cas d’augmentation de capital décidée par le conseil d’administration dans le cadre du capital autorisé, toutes les primes d’émission comptabilisées, le cas échéant, seront comptabilisées conformément aux dispositions des présents statuts.<br><br> <br><br><br> <br>Le conseil d’administration est autorisé, dans l’exercice de ses pouvoirs dans le cadre du capital autorisé, à limiter ou à supprimer, dans l’intérêt de la société, le droit de préférence des actionnaires. Cette limitation ou suppression du droit de préférence peut également être faite en faveur des membres du personnel de la société ou de ses filiales, ou en faveur d’une ou plusieurs personnes autres que les membres du personnel de la société ou de ses filiales.<br><br> <br><br><br> <br>Le conseil d’administration est autorisé, avec droit de substitution, à modifier les statuts, après chaque augmentation de capital intervenue dans le cadre du capital autorisé, afin de les mettre en conformité avec la nouvelle situation du capital et des actions.”	The general shareholders’<br> meeting resolves to renew the authorisation to the board of directors to increase the share capital in one or several times, during a<br> period of five (5) years as from the publication in the Annexes to the Belgian Official Gazette of this authorisation, with an aggregate<br> amount equal to up to 100% of the amount of the share capital of the Company, and this in accordance with the terms and conditions set<br> forth in the special report of the board of directors prepared in accordance with article 7:199 of the Belgian Companies and Associations<br> Code, as referred to in agenda item 3 of this extraordinary general shareholders’ meeting. Consequently, the general shareholders’ meeting<br> resolves to delete article 6 “Authorised capital” of the articles of association of the Company entirely and to replace it with<br> the following text (whereby the date referred to in the sub-section between square brackets shall be the date of the general shareholders’<br> meeting approving the renewed authorised capital, and the amount referred to in the sub-section between brackets shall be the amount of<br> the Company’s share capital at the time of the general shareholders’ meeting approving the authorised capital):<br><br> <br><br><br> <br>“Article 6: Authorised capital<br><br> <br><br><br> <br>The board of directors is authorised to increase the share capital of the company on one or several occasions by a maximum aggregate amount of [100% of the company’s share capital at the time of the adoption of the new authorised capital].<br><br> <br><br><br> <br>The board of directors may increase the share capital by contributions in cash or in kind, by capitalisation of reserves, whether available or unavailable for distribution, and capitalisation of issue premiums, with or without the issuance of new shares, with or without voting rights, that will have the rights as will be determined by the board of directors. The board of directors is also authorised to use this authorisation for the issuance of convertible bonds or subscription rights, bonds with subscription rights or other securities.<br><br> <br><br><br> <br>This authorisation is valid for a period of five years as from the date of publication in the Annexes to the Belgian Official Gazette of an extract of the minutes of the extraordinary general shareholders’ meeting of the company held on [date of the general shareholders’ meeting approving the authorised capital].<br><br> <br><br><br> <br>In the event of a capital increase decided by the board of directors within the framework of the authorised capital, all issue premiums booked, if any, will be accounted for in accordance with the provisions of these articles of association.<br><br> <br><br><br> <br>The board of directors is authorised, when exercising its powers within the framework of the authorised capital, to restrict or cancel, in the interest of the company, the preferential subscription rights of the shareholders. This restriction or cancellation of the preferential subscription rights can also be done in favour of members of the personnel of the company or of its subsidiaries, or in favour of one or more persons other than members of the personnel of the company or of its subsidiaries.<br><br> <br><br><br> <br>The board of directors is authorised, with the right of substitution, to amend the articles of association, after each capital increase that has occurred within the framework of the authorised capital, in order to bring them in conformity with the new situation of the share capital and the shares.”
Assemblée Générale Extraordinaire des Actionnaires de MDxHealth SA - Procuration
---	---
Extraordinary General Shareholders’ Meeting of MDxHealth SA - Proxy	8/10
► Instruction de vote:	► Voting instruction:
---	---
0 Pour / For	0 Contre / Against	0 Abstention
---	---	---
II.Si<br> l’assemblée générale extraordinaire des actionnaires sont ajournées ou suspendues, le mandataire spécial<br> aura les pouvoirs de représenter le soussigné à l’assemblée générale des actionnaires qui seront<br> tenues avec le même ordre du jour, le cas échéant:<br><br> <br><br><br> <br>☐<br> oui<br><br> <br>☐<br> non<br><br> <br><br><br> <br>Veuillez remplir la case appropriée. Une absence d’instruction ou si, pour quelque raison, il y a une absence de clarté à propos de l’instruction donnée, le soussigné sera supposé avoir choisi “oui”. Veuillez noter qu’aux fins de s’appliquer à telle assemblée subséquente, les titulaires de titres doivent s’enregistrer à nouveau pour cette assemblée.<br><br> <br><br><br> <br>Si, pendant l’assemblée, il y a des modifications<br> à une proposition de résolution ou une nouvelle proposition de résolution:^1^<br><br> <br><br><br> <br>☐<br> le mandataire spécial votera pour la résolution modifiée ou nouvelle<br><br> <br>☐<br> le mandataire spécial votera contre la résolution modifiée ou nouvelle<br><br> <br>☐<br> le mandataire spécial s’abstiendra de voter sur la résolution modifiée ou nouvelle<br><br> <br>☐<br> le mandataire spécial votera sur la résolution modifiée ou nouvelle selon la manière supportée ou recommandée<br> par le conseil d’administration de la Société<br><br> <br><br><br> <br>^1^Veuillez cocher tel qu’approprié. Une absence d’instruction sera interprétée comme une instruction de voter pour la résolution modifiée ou nouvelle selon la manière supportée ou recommandée par le conseil d’administration de la Société.<br><br> <br><br><br> <br>III.Le<br> mandataire spécial est autorisé, au nom et pour le compte du soussigné, à signer toutes listes de présence<br> et procès-verbaux, à participer à toutes les délibérations, à prendre part au vote sur toutes<br> les décisions ou sujets pouvant, conformément à cet ordre du jour, être soumis à l’assemblée.<br><br> <br><br><br> <br>IV.Le<br> mandataire spécial est autorisé, en général, à faire tout ce qui semble nécessaire et/ou utile<br> pour exercer cette procuration.	II.In<br> case the aforementioned extraordinary general shareholders’ meeting would be postponed or suspended, the special proxy holder shall have<br> the power to represent the undersigned at the general shareholders’ meeting that would be held having the same agenda, as relevant:<br><br> <br><br><br> <br>☐<br> yes<br><br> <br>☐<br> no<br><br> <br><br><br> <br>Please tick the appropriate box. In the absence of an instruction, or if, for whatever reason, there is a lack of clarity with regard to the instruction given, the undersigned shall be deemed to have selected “yes”. Please note that in order to apply for such subsequent meeting, holders of securities must again register for such meeting.<br><br> <br><br><br> <br>In case of amendments during the meeting to a<br> proposed resolution or a new proposed resolution:^1^<br><br> <br><br><br> <br>☐<br> the proxy holder shall vote for the amended or new resolution<br><br> <br>☐<br> the proxy holder shall vote against the amended or new resolution<br><br> <br>☐<br> the proxy holder shall abstain from the vote on the amended or new resolution<br><br> <br>☐<br> the proxy holder shall vote on the amended or new resolution in the manner supported or recommended by the board of directors of the Company<br><br> <br><br><br> <br>^1^ Please complete as appropriate. An absence of instruction shall be tantamount to an instruction to vote for the amended or new resolution as will be supported or recommended by the board of directors of the Company.<br><br> <br><br><br> <br>III.The<br> special proxy holder has the power to, in the name of and on behalf of the undersigned, sign all attendance lists and minutes, participate<br> in all deliberations, vote with respect to all decisions or items that can, pursuant to this agenda, be presented to said meeting.<br><br> <br><br><br> <br>IV.In<br> general, the special proxy holder has the power to do all that appears necessary and/or useful for the exercise of this proxy.
---	---
Assemblée Générale Extraordinaire des Actionnaires de MDxHealth SA - Procuration
---	---
Extraordinary General Shareholders’ Meeting of MDxHealth SA - Proxy	9/10
Le/la soussigné(e) ratifie et approuve<br> par la présente tous les actes accomplis par le mandataire spécial susmentionné. Le mandataire spécial votera<br> pour le compte du/de la soussigné(s) conformément aux instructions spécifiques données ci-dessus.<br><br> <br><br><br> <br>La présente procuration vaut également<br>notification au sens de l’article 7:134, §2, alinéa 3 du Code des sociétés et des associations en ce qui concerne<br>l’assemblée générale extraordinaire des actionnaires de la Société à tenir le vendredi 30 juin<br>2023.<br><br> <br><br><br> <br>Le soussigné confirme que la traduction<br> anglaise de la présente procuration n’est qu’une traduction libre en anglais et à titre informatif uniquement, et que la<br> version française prévaut sur la version anglaise.<br><br> <br><br><br> <br><br><br> <br>BON POUR PROCURATION	The undersigned hereby ratifies and approves all<br> acts carried out by the aforementioned proxy holder. The special proxy holder will vote on behalf of the undersigned in accordance with<br> the specific instructions given above.<br><br> <br><br><br> <br>The present proxy shall also serve as notification<br> within the meaning of article 7:134, §2, paragraph 3 of the Belgian Companies and Associations Code with respect to the extraordinary<br> general shareholders’ meeting of the Company to be held on Friday 30 June 2023.<br><br> <br><br><br> <br>The undersigned confirms that the English translation<br> of the present proxy is a free English translation and for information purposes only, and that the French version shall prevail over the<br> English version.<br><br> <br><br><br> <br><br><br> <br>GOOD FOR PROXY
---	---
……………………………… 2023 <br><br>(date)
……………………………………………………..<br><br> <br>(nom / name)
……………………………………………………..<br><br> <br>(signature)
Assemblée Générale Extraordinaire des Actionnaires de MDxHealth SA - Procuration
---	---
Extraordinary General Shareholders’ Meeting of MDxHealth SA - Proxy	10/10

Exhibit 99.4

AssemblÉe gÉnÉrale extraordinaire des Actionnaires<br><br> <br>30 juin 2023	extraordinary general shareholders’ meeting 30 June 2023
formulaire de vote par correspondance	Voting by mail form
Ce formulaire doit être utilisé par<br> les titulaires de titres de MDxHealth SA (la “Société”) qui désirent voter par correspondance<br> à l’assemblée générale extraordinaire des actionnaires de la Société à tenir le vendredi<br> 30 juin 2023 à 9h00 (heure belge).<br><br> <br><br><br> <br>Le formulaire de vote par correspondance doit<br> être signé par écrit ou électroniquement. Si une signature électronique est utilisée, elle doit<br> être une signature électronique qualifiée au sens du Règlement (UE) n° 910/2014 du Parlement européen<br> et du Conseil du 23 juillet 2014 sur l’identification électronique et les services de confiance pour les transactions électroniques<br> au sein du marché intérieur et abrogeant la directive 1999/93/CE, tel que modifié.<br><br> <br><br><br> <br>Le formulaire de vote par correspondance signé<br> et complété doit parvenir à la Société au plus tard le sixième jour calendrier qui précède<br> l’assemblée générale extraordinaire des actionnaires, soit le, ou avant le, samedi 24 juin 2023 au<br> plus tard. Jusqu’à cette date, les formulaires peuvent être envoyées à l’adresse suivante :<br><br> <br><br><br> <br>MDxHealth SA<br><br> A l’attention de M. Ron Kalfus<br><br> Secrétaire de la Société<br><br> CAP Business Center<br><br> <br>Zone Industrielle des Hauts-Sarts<br><br> <br>Rue d’Abhooz 31,<br><br> 4040 Herstal<br><br> <br>Belgique<br><br> <br><br><br> <br>ou par courrier électronique à :<br><br> <br>agsm@mdxhealth.com<br><br> <br><br><br> <br>Les titulaires de titres de la Société<br> qui désirent être représentés par voter par correspondance doivent aussi s’enregistrer à l’assemblée<br> générale extraordinaire des actionnaires, tel que décrit dans l’invitation à l’assemblée générale<br> extraordinaire des actionnaires. Les titulaires de titres dématérialisés doivent joindre à ce formulaire de<br> vote par correspondance un certificat délivré par le teneur de compte agréé, l’organisme de liquidation compétent,<br> ou de l’intermédiaire financier pour les titres concernés, confirmant le nombre de titres ayant été enregistrés<br> à leur nom à la date d’enregistrement (soit le vendredi 16 juin 2023, à minuit (00h00, heure belge)) et avec lesquelles<br> ils veulent participer à l’assemblée générale extraordinaire des actionnaires.<br><br> <br><br><br> <br>La date limite pour la communication de ce<br>vote par correspondance est un samedi, pendant laquelle il n’y a généralement pas de service postal ordinaire. Ainsi, la<br>Société recommande d’utiliser le courrier électronique pour toute communication avec la Société concernant<br>l’assemblée générale d’actionnaires.	This form should be used by holders of securities<br> of MDxHealth SA (the “Company”) who want to vote by mail at the extraordinary general shareholders’ meeting of the Company<br> to be held on Friday, 30 June 2023, at 9:00 a.m. (Belgian time).<br><br> <br><br><br> <br>The voting by mail form must be signed in writing<br> or electronically. In the event an electronic signature is used, it must be a qualified electronic signature in the sense of Regulation<br> (EU) No 910/2014 of the European Parliament and of the Council of 23 July 2014 on electronic identification and trust services for electronic<br> transactions in the internal market and repealing Directive 1999/93/EC, as amended.<br><br> <br><br><br> <br>The signed and completed voting by mail form must<br> reach the Company at the latest on the sixth calendar day prior to the extraordinary general shareholders’ meeting, i.e. on or before Saturday, 24 June 2023 at the latest. Until this date, forms can be sent to the following address:<br><br> <br><br><br> <br>MDxHealth SA<br><br> Attention Mr. Ron Kalfus<br><br> Company Secretary<br><br> <br>CAP Business Center<br><br> <br>Zone Industrielle des Hauts-Sarts<br><br> Rue d’Abhooz, 31<br><br> 4040 Herstal,<br><br> Belgium<br><br> <br><br><br> <br>or by e-mail to:<br><br> <br>agsm@mdxhealth.com<br><br> <br><br><br> <br>Holders of securities of the Company who wish<br> to vote by mail must also register for the extraordinary general shareholders’ meeting, as described in the notice convening the extraordinary<br> general shareholders’ meeting. Holders of dematerialised securities must attach to the present voting by mail form a certificate issued<br> by the certified account holder, the applicable settlement institution, or the relevant financial intermediary for the securities concerned,<br> confirming the number of securities that have been registered in their name on the registration date (i.e., Friday, 16 June 2023, at midnight<br> (12:00 a.m., Belgian time)), with which they want to participate to the extraordinary general shareholders’ meeting.<br><br> <br><br><br> <br>The deadline for the submission of this voting<br> by mail form is on a Saturday, during which there is usually no ordinary postal service. Therefore, the Company recommends to use e-mail<br> for all communication with the Company regarding the general shareholders’ meeting.
Le/La soussigné(e),	The undersigned,
---	---
Prénom / First name:	……………………………………………………………………………………………………
---	---
Nom de famille / Family name:	……………………………………………………………………………………………………
Adresse / Address:	……………………………………………………………………………………………………
ou / or
Dénomination / Corporate name:	……………………………………………………………………………………………………
Forme juridique / Corporate form:	……………………………………………………………………………………………………
Siège / Registered office:	……………………………………………………………………………………………………
	……………………………………………………………………………………………………
Représenté par (prénom, nom de famille et	……………………………………………………………………………………………………
qualité) / Represented by (first name, family	……………………………………………………………………………………………………
name and capacity):	……………………………………………………………………………………………………
Assemblée Générale Extraordinaire des Actionnaires de MDxHealth SA - Formulaire de vote par correspondence Extraordinary General Shareholders’ Meeting of MDxHealth SA - Voting by mail form	1/9
---	---
titulaire du (des) nombre(s) suivant(s) de titres émis par MDxHealth SA, ayant son siège au CAP Business Center, Zone Industrielle des Hauts-Sarts, Rue d’Abhooz 31, 4040 Herstal, Belgique,	owner of the following number of securities issued by MDxHealth SA, with its registered office at CAP Business Center, Zone Industrielle des Hauts-Sarts, rue d’Abhooz 31, 4040 Herstal, Belgium,
---	---
Nombre d’actions / Number of shares: ………………..
---
Forme des actions susmentionnées / Form of the above mentioned shares:
(veuillez cocher la case appropriée / please tick the appropriate box)
☐ Nominatives / Registered
☐ Dématérialisées / Dematerialised
Nombre de droits de souscription / <br><br>Number of subscription rights: ^1^ ………………..
^1^	Conformément à l’article 7:135 du Code des sociétés et des associations, les titulaires de droits de souscription ont le droit de participer à l’assemblée générale des actionnaires mais seulement avec voix consultative.	^1^	Pursuant to article 7:135 of the Belgian Companies and Associations Code, the holders of subscription rights have the right to attend the shareholders’ meeting, but only with an advisory vote.
---	---	---	---
	vote irrévocablement, comme indiqué dans les cases correspondantes ci-dessous, sur les points inscrits à l’ordre du jour suivant : ^2^		votes irrevocably, as indicated in the corresponding boxes below, on the items on the following agenda: ^2^
^2^	Veuillez indiquer l’instruction de vote dans les cases appropriées pour les points à l’ordre du jour. En l’absence d’une instruction de vote pour un point de l’ordre du jour, ou dans le cas où, pour quelque raison que ce soit, il y aurait un manque de clarté concernant les instructions de vote, le/la soussigné(e) sera présumé(e) avoir voté “en faveur” des résolutions proposées soutenues par le conseil d’administration.	^2^	Please indicate the voting instructions in the appropriate boxes of the agenda items. In the absence of voting instructions for any agenda item or in the event that, for any reason whatsoever, any uncertainty would arise with regards to the voting instructions, the undersigned will be presumed to have voted in favour of the proposed resolutions supported by the board of directors.
ORDREDU JOUR<br><br> <br>ASSEMBLEE GENERALE EXTRAORDINAIRE	agenda<br><br> <br>extraordinary general meeting
---	---
1. Communication<br> des rapports - Plan d’Option sur Action de 2023<br><br> <br><br><br> <br>Communication des, discussion sur:<br><br> <br><br><br> <br>a) le<br> rapport du conseil d’administration de la Société conformément aux articles 7:180 et 7:191 du Code des sociétés<br> et associations relatif à la proposition d’émettre 5.000.000 nouveaux droits de souscription de la Société<br> (les “2023 Share Options”), en vertu d’un plan d’option sur action dénommé “le Plan d’Option sur Action<br> de 2023”, et de supprimer, dans l’intérêt de la Société, le droit de préférence des actionnaires<br> existants de la Société et, pour autant que de besoin, des détenteurs de droits de souscription en circulation (share options) ou American Depositary Shares (“ADSs”) de la Société, en faveur des membres du personnel<br> de la Société et de ses filiales de temps à autre, au sens de l’article 1:27 du Code des sociétés et<br> des associations (les “Participants Sélectionnés”); et<br><br> <br><br><br> <br>b) le<br> rapport du commissaire de la Société conformément aux articles 7:180 et 7:191 du Code des sociétés<br> et des associations concernant la proposition d’émettre 5.000.000 2023 Share Options et de supprimer, dans l’intérêt<br> de la Société, le droit de préférence des actionnaires existants de la Société et, pour autant<br> que de besoin, des détenteurs de droits de souscription en circulation (share options) ou ADSs de la Société,<br> en faveur des Participant Sélectionnés.	1. Submission<br> of reports - 2023 Share Option Plan<br><br> <br><br><br> <br>Submission of, discussion on:<br><br> <br><br><br> <br>a) the<br> report of the board of directors of the Company in accordance with articles 7:180 and 7:191 of the Belgian Companies and Associations<br> Code in relation to the proposal to issue 5,000,000 new subscription rights for shares of the Company (the “2023 Share Options”),<br> pursuant to a share option plan named “the 2023 Share Option Plan”, and to dis-apply, in the interest of the Company, the preferential<br> subscription right of the existing shareholders of the Company and, insofar as required, of the holders of outstanding subscription rights<br> (share options) or American Depositary Shares (“ADSs”) of the Company, for the benefit of the members of the personnel<br> of the Company and its subsidiaries from time to time, within the meaning of article 1:27 of the Belgian Companies and Associations Code<br> (the “Selected Participant”); and<br><br> <br><br><br> <br>b) the<br> report of the statutory auditor of the Company in accordance with articles 7:180 and 7:191 of the Belgian Companies and Associations Code<br> in relation to the proposal to issue 5,000,000 2023 Share Options, and to dis-apply, in the interest of the Company, the preferential<br> subscription right of the existing shareholders of the Company and, insofar as required, of the holders of outstanding subscription rights<br> (share options) or ADSs of the Company, to the benefit of the Selected Participants.
---	---
Assemblée Générale Extraordinaire des Actionnaires de MDxHealth SA - Formulaire de vote par correspondance Extraordinary General Shareholders’ Meeting of MDxHealth SA - Voting by mail form	2/9
---	---
2. Proposition d’émettre<br>5.000.000 2023 Share Options	2. Proposal to issue 5,000,000<br>2023 Share Options
---	---
► Proposition de résolution:	► Proposed resolution:
L’assemblée<br>générale des actionnaires décide d’approuver l’émission de 5.000.000 2023 Share Options, en vertu d’un plan<br>d’option sur action dénommé “le Plan d’Option sur Action de 2023”, et de supprimer, dans l’intérêt<br>de la Société, le droit de préférence des actionnaires existants de la Société et, pour autant<br>que de besoin, des détenteurs de droits de souscription en circulation (share options) ou ADSs de la Société,<br>en faveur des Participants Sélectionnés. En conséquence, le conseil d’administration décide de ce qui suit:	The general shareholders’ meeting resolves to approve the issuance<br>of 5,000,000 2023 Share Options, pursuant to a share option plan named “the 2023 Share Option Plan”, and to dis-apply, in the<br>interest of the Company, the preferential subscription right of the existing shareholders of the Company and, insofar as required, of<br>the holders of outstanding subscription rights (share options) or ADSs of the Company, for the benefit of Selected Participant. In view<br>thereof, the general shareholders’ meeting resolves as follows:
(a) Termes<br>et conditions des 2023 Share Options: Les termes et conditions des 2023 Share Options (inclus, mais sans s’y limiter, le prix d’exercice<br>des 2023 Share Options) seront tels que figurant dans l’annexe au rapport du conseil d’administration visé au point 1.(a) de l’ordre<br>du jour (aux fins de la présente résolution, le “Plan”), dont une copie restera jointe au présent<br>procès-verbal. Les 2023 Share Options ont une durée de 10 ans à partir de leur date d’émission.<br><br><br><br><br><br><br><br>(b) Actions<br>sous-jacentes: Chaque 2023 Share Option donne à son détenteur le droit de souscrire à une nouvelle action qui<br>sera émise par la Société. Les nouvelles actions à émettre lors de l’exercice des 2023 Share Options<br>auront les mêmes droits et avantages, et seront à tous égards pari passu, en ce compris en ce qui concerne<br>les droits aux dividendes et autres distributions, avec les actions existantes et en circulation de la Société au moment<br>de leur émission, et auront droit aux dividendes et autres distributions pour lesquelles la date d’enregistrement ou la date d’échéance<br>tombe à, ou après la date d’émission des actions.<br><br><br><br><br><br><br><br>(c) Suppression<br>du droit de préférence en faveur des Participants Sélectionnés: L’assemblée générale<br>des actionnaires décide, conformément à l’article 7:191 du Code des sociétés et des associations, de<br>supprimer, dans l’intérêt de la Société, le droit de préférence des actionnaires existants de<br>la Société et, pour autant que de besoin, des détenteurs de droits de souscription en circulation (share options)<br>de la Société, en faveur des Participants Sélectionnés, et d’approuver la possibilité pour la<br>Société d’octroyer les 2023 Share Options aux Participants Sélectionnés, comme expliqué plus<br>en détail dans le rapport du conseil d’administration visé au point 1.(a) de l’ordre du jour et dans les termes et conditions<br>du Plan.<br><br><br><br><br><br><br><br>(d) Confirmation<br>de la souscription de 2023 Share Options par la Société: L’assemblée générale des actionnaires<br>décide d’approuver et de confirmer que la Société sera en mesure de souscrire aux 2023 Share Options, en vue de créer<br>un pool de 2023 Share Options disponible pour des octrois ultérieurs aux Participants Sélectionnés. La Société<br>ne peut cependant pas exercer les 2023 Share Options pour son compte propre.	(a) Terms<br>and conditions of the 2023 Share Options: The terms and conditions of the 2023 Share Options (including, but not limited to, the exercise<br>price of the 2023 Share Options) shall be as set out in the annex to the report of the board of directors referred to in item 1.(a) of<br>the agenda (for the purpose of this resolution, the “Plan”), a copy of which shall remain attached to the minutes reflecting<br>the present resolution. The 2023 Share Options have a term of ten years as from their issue date.<br><br><br><br><br><br><br><br>(b) Underlying<br>shares: Each 2023 Share Option shall entitle the holder thereof to subscribe for one new share to be issued by the Company. The new<br>shares to be issued at the occasion of the exercise of the 2023 Share Options shall have the same rights and benefits as, and rank paripassu in all respects, including as to entitlements to dividends and other distributions, with the existing and outstanding shares<br>of the Company at the moment of their issuance, and will be entitled to dividends and other distributions in respect of which the relevant<br>record date or due date falls on or after the date of issue of the shares.<br><br><br><br><br><br><br><br>(c) Dis-application<br>of the preferential subscription right for the benefit of the Selected Participants: The general shareholders’ meeting resolves, in<br>accordance with article 7:191 of the Belgian Companies and Associations Code, to dis-apply, in the interest of the Company, the preferential<br>subscription right of the existing shareholders of the Company and, insofar as required, of the holders of outstanding subscription rights<br>(share options) or ADSs of the Company, for the benefit of the Selected Participants, and to approve the possibility for the Company to<br>grant the 2023 Share Options to the Selected Participants, as further explained in the report of the board of directors referred to in<br>item 1.(a) of the agenda and the terms and conditions of the Plan.<br><br><br><br><br><br><br><br>(d) Confirmation<br>of the subscription of 2023 Share Options by the Company: The general shareholders’ meeting resolves to approve and confirm that the<br>Company will be able to subscribe for the 2023 Share Options, with a view to creating a pool of outstanding 2023 Share Options available<br>for further grants to Selected Participants. The Company may not, however, exercise the 2023 Share Options for its own account.
Assemblée Générale Extraordinaire des Actionnaires de MDxHealth SA - Formulaire de vote par correspondance Extraordinary General Shareholders’ Meeting of MDxHealth SA - Voting by mail form	3/9
---	---
(e) Augmentation<br>de capital conditionnelle et émission de nouvelles actions: L’assemblée générale des actionnaires décide,<br>sous réserve et dans la mesure de l’exercice des 2023 Share Options, d’augmenter le capital de la Société et d’émettre<br>le nombre approprié de nouvelles actions pouvant être émises lors de l’exercice des 2023 Share Options. Sous réserve<br>et conformément aux dispositions du Plan, lors de l’exercice des 2023 Share Options et de l’émission de nouvelles actions,<br>le montant total du prix d’exercice des 2023 Share Options sera affecté au capital de la Société. Dans la mesure<br>où le montant du prix d’exercice des 2023 Share Options, par action à émettre lors de l’exercice des 2023 Share Options,<br>excède le pair comptable des actions de la Société existantes alors immédiatement avant l’émission<br>des nouvelles actions concernées, une partie du prix d’exercice, par action à émettre lors de l’exercice des 2023<br>Share Options, égale à ce pair comptable sera comptabilisée en capital, le solde étant comptabilisé<br>en prime d’émission. Suite à l’augmentation de capital et à l’émission de nouvelles actions, chaque action<br>nouvelle et existante représentera la même fraction du capital de la Société.<br><br><br><br><br><br><br><br>(f) Prime<br>d’émission: Toute prime d’émission qui sera comptabilisée en relation avec les 2023 Share Options sera comptabilisée<br>sur un compte indisponible au passif du bilan de la Société dans ses capitaux propres, et le compte sur lequel la prime<br>d’émission sera comptabilisée constituera, au même titre que le capital de la Société, la garantie des<br>tiers et, sauf possibilité de capitalisation de ces réserves, ne pourra être réduit ou supprimé que<br>par une décision de l’assemblée générale des actionnaires statuant dans les conditions requises pour la modification<br>des statuts de la Société.<br><br><br><br><br><br><br><br>(g) Procurations:<br>Le conseil d’administration est autorisé à mettre en œuvre et à exécuter les décisions prises<br>par l’assemblée générale des actionnaires en rapport avec les 2023 Share Options, et à prendre toutes les<br>mesures et à accomplir toutes les formalités requises en vertu du Plan, des statuts de la Société et de la<br>loi applicable afin d’émettre ou transférer les actions lors de l’exercice des 2023 Share Options. En outre, chaque administrateur<br>de la Société, Joe Sollee et Ron Kalfus, chacun agissant individuellement et avec possibilité de subdélégation<br>et pouvoir de subrogation, auront le pouvoir, lors de l’exercice des 2023 Share Options, (i) de procéder à la constatation<br>(A) de l’augmentation de capital et de l’émission de nouvelles actions résultant de cet exercice, (B) de l’allocation du<br>capital et (le cas échéant) de la prime d’émission, et (C) de la modification des statuts de la Société<br>afin de refléter le nouveau capital et nombre d’actions en circulation suite à l’exercice des 2023 Share Options, (ii) de<br>signer et remettre, au nom de la Société, la documentation Euroclear, Euronext et bancaire pertinente, le registre des actions<br>et tous les documents nécessaires en relation avec l’émission et la livraison des actions au Participant Sélectionné,<br>et (iii) faire tout ce qui peut être nécessaire ou utile (y compris, mais sans s’y limiter, la préparation et l’exécution<br>de tous les documents et formulaires) pour l’admission des actions émises lors de l’exercice des 2023 Share Options à la<br>négociation sur le marché réglementé d’Euronext Brussels (ou tout autre marché sur lequel les actions<br>de la Société seront négociées à ce moment).	(e) Conditional<br>capital increase and issue of new shares: The general shareholders’ meeting resolves, subject to, and to the extent of the exercise<br>of 2023 Share Options, to increase the Company’s share capital and to issue the relevant number of new shares issuable upon the exercise<br>of the 2023 Share Options. Subject to, and in accordance with, the provisions of the Plan, upon exercise of the 2023 Share Options and<br>issue of new shares, the aggregate amount of the exercise price of the 2023 Share Options will be allocated to the share capital of the<br>Company. To the extent that the amount of the exercise price of the 2023 Share Options, per share to be issued upon exercise of the 2023<br>Share Options, exceeds the fractional value of the then existing shares of the Company existing immediately prior to the issue of the<br>new shares concerned, a part of the exercise price, per share to be issued upon exercise of the 2023 Share Options, equal to such fractional<br>value shall be booked as share capital, whereby the balance shall be booked as issue premium. Following the capital increase and issuance<br>of new shares, each new and existing share shall represent the same fraction of the share capital of the Company.<br><br><br><br><br><br><br><br>(f) Issue<br>premium: Any issue premium that will be booked in connection with the 2023 Share Options shall be accounted for on a non-distributable<br>account on the liabilities side of the Company’s balance sheet under its net equity, and the account on which the issue premium will be<br>booked shall, like the share capital, serve as a guarantee for third parties and can only be reduced on the basis of a lawful resolution<br>of the general shareholders’ meeting passed in the manner required for an amendments to the Company’s articles of association.<br><br><br><br><br><br><br><br>(g) Powers<br>of attorney: The board of directors is authorised to implement and execute the resolutions passed by the general shareholders’ meeting<br>in connection with the 2023 Share Options, and to take all steps and carry out all formalities that shall be required by virtue of the<br>Plan, the Company’s articles of association and applicable law in order to issue or transfer the shares upon exercise of the 2023 Share<br>Options. Furthermore, each of the Company’s directors, Joe Sollee and Ron Kalfus, each such person acting individually and with possibility<br>of sub-delegation and the power of subrogation, shall have the power, upon exercise of the 2023 Share Options, (i) to proceed with the<br>recording of (A) the capital increase and issue of new shares resulting from such exercise, (B) the allocation of the share capital and<br>(as applicable) the issue premium, and (C) the amendment of the Company’s articles of association in order to reflect the new share capital<br>and number of outstanding shares following the exercise of the 2023 Share Options, (ii) to sign and deliver, on behalf of the Company,<br>the relevant Euroclear, Euronext and bank documentation, the share register and all necessary documents in connection with the issuance<br>and delivery of the shares to the beneficiary, and (iii) to do whatever may be necessary or useful (including but not limited to the preparation<br>and execution of all documents and forms) for the admission of the shares issued upon the exercise of the 2023 Share Options to trading<br>on the regulated market of Euronext Brussels (or such other markets on which the Company’s shares will be trading at that time).
---	---
Assemblée Générale Extraordinaire des Actionnaires de MDxHealth SA - Formulaire de vote par correspondance Extraordinary General Shareholders’ Meeting of MDxHealth SA - Voting by mail form	4/9
---	---
(h) Renonciation:<br>L’assemblée générale des actionnaires reconnaît que les 2023 Share Options qui seront octroyés dans<br>le cadre du “Plan d’Option sur Action de 2023” ne seront pas considérées comme une “rémunération<br>variable”, une “rémunération fixe” ou une “rémunération annuelle” au sens du Code<br>des sociétés et associations (y compris, sans limitation, aux fins des articles 3:6, §3, 7:89/1, 7:90, 7:91, 7:92,<br>7:100, 7:108 et 7:121 du Code des sociétés et associations) et du Code belge de gouvernance d’entreprise 2020 (y compris,<br>sans limitation, aux fins de la disposition 11 du Code belge de gouvernance d’entreprise 2020). L’assemblée générale<br>des actionnaires approuve les conditions et mécanismes d’acquisition définitive des 2023 Share Options, telles qu’elles<br>sont inclues dans le Plan. Les dispositions des articles 7:91, 7:108 et 7:121 (selon le cas) du Code des sociétés et associations<br>sont expressément écartées en ce qui concerne le Plan des 2023 Share Options.<br><br><br><br><br><br><br><br>(i) Approbation<br>conformément à l’article 7:151 du Code des sociétés et des associations: L’assemblée générale<br>des actionnaires décide de prendre note, d’approuver et de ratifier, pour autant que de besoin conformément à l’article<br>7:151 du Code des sociétés et des associations, toutes les clauses incluses dans le Plan, qui entrent en vigueur au moment<br>où un changement de contrôle se produit et qui tombent ou pourraient être considérées comme tombant sous<br>le coup de l’article 7:151 du Code des sociétés et associations (relatif à l’octroi de droits à des tiers<br>affectant substantiellement le patrimoine de la Société ou donnant naissance à une dette ou à un engagement<br>substantiel à sa charge, lorsque l’exercice de ces droits dépend du lancement d’une offre publique d’acquisition sur les<br>actions de la Société ou d’un changement du contrôle exercé sur), y compris, sans limitation, le mécanisme<br>d’acquisition accélérée automatique lors d’une acquisition tel que défini dans le Plan. L’assemblée<br>générale des actionnaires accorde une procuration spéciale à chaque administrateur de la Société,<br>agissant seul et avec pouvoir de substitution, aux fins d’accomplir les formalités requises par l’article 7:151 du Code des sociétés<br>et des associations en ce qui concerne la présente résolution.	(h) Waiver:<br>The general shareholders’ meeting acknowledges that the 2023 Share Options to be granted under the “2023 Share Option Plan”<br>shall not be considered “variable remuneration”, “fixed remuneration” or “annual remuneration” within the<br>meaning of the Belgian Companies and Associations Code (including, without limitation, for the purpose of articles 3:6, §3, 7:89/1,<br>7:90, 7:91, 7:92, 7:100, 7:108 and 7:121 of the Belgian Companies and Associations Code) and the 2020 Corporate Governance Code (including,<br>without limitation, for the purpose of provision 11 of the 2020 Corporate Governance Code). The general shareholders’ meeting approves<br>the vesting conditions and mechanisms of the 2023 Share Options, as included in the Plan. The provisions of articles 7:91, 7:108 and 7:121<br>(as applicable) of the Belgian Companies and Associations Code are expressly dis-applied in relation to the 2023 Share Option Plan.<br><br><br><br><br><br><br><br>(i) Approval in accordance<br>with article 7:151 of the Belgian Companies and Associations Code: The general shareholders’ meeting resolves to take note, approve<br>and ratify, insofar as required in accordance with article 7:151 of the Belgian Companies and Associations Code, all clauses included<br>in the Plan, which come into effect at the moment a change of control occurs and which fall or could be considered to fall within the<br>scope of article 7:151 of the Belgian Companies and Associations Code (relating to the granting of rights to third parties that substantially<br>affect the Company’s assets and liabilities, or give rise to a substantial debt or commitment on its behalf, when the exercise of these<br>rights is subject to the launching of a public takeover bid on the shares of the Company or to a change in the control exercised over<br>it), including, without limitation, the automatic accelerated vesting mechanism upon acquisition as defined in the Plan. The general shareholders’<br>meeting grants a special power of attorney to each director of the Company, acting alone and with power of substitution, for the purpose<br>of carrying out the formalities required by article 7:151 of the Belgian Companies and Associations Code with respect to this resolution.
---	---
Assemblée Générale Extraordinaire des Actionnaires de MDxHealth SA - Formulaire de vote par correspondance Extraordinary General Shareholders’ Meeting of MDxHealth SA - Voting by mail form	5/9
---	---
► Instruction de vote:	► Voting instruction:
---	---
0 Pour / For	0 Contre / Against	0 Abstention
---	---	---
3. Communication du rapport spécial du conseil d’administration conformément à l’article 7:199 du Code des sociétés et des associations relatif à la proposition de renouveler le capital autorisé	3. Submission of the special report of the board of directors in accordance with article 7:199 of the Belgian Companies and Associations Code relating to the proposal to renew the authorised capital
---	---
Considération, discussion et communication du rapport spécial<br>du conseil d’administration conformément à l’article 7:199 du Code des sociétés et des associations relatif<br>à la proposition de renouveler les pouvoirs conférés au conseil d’administration dans le cadre du capital autorisé,<br>tel que repris ci-dessous au point 4 de l’ordre du jour de l’assemblée générale extraordinaire des actionnaires,<br>et exposant les circonstances spécifiques dans lesquelles le conseil d’administration pourra utiliser ses pouvoirs dans le cadre<br>du capital autorisé, et les objectifs qu’il devra poursuivre.	Consideration, discussion and submission of the special report of the<br>board of directors in accordance with article 7:199 of the Belgian Companies and Associations Code relating to the proposal to renew<br>the powers granted to the board of directors under the authorised capital, as set out below in item 4 of the agenda of the extraordinary<br>general shareholders’ meeting, and setting out the specific circumstances in which the board of directors will be able to use its powers<br>under the authorised capital, and the purposes that it should pursue.
4. Renouvellement de<br>l’autorisation au conseil d’administration d’augmenter le capital dans le cadre du capital autorisé	4. Renewal of the authorisation to the board of directors to increase the share capital within the framework of the authorised capital
Afin de permettre au conseil d’administration de disposer de la flexibilité nécessaire pour lever des fonds propres supplémentaires lorsque le besoin s’en fait sentir ou qu’une opportunité se présente, le conseil d’administration propose de lui accorder des pouvoirs limités dans le cadre du capital autorisé pour augmenter le capital de la Société d’un montant maximum égal à 100% du montant du capital de la Société pendant une période de cinq (5) ans, le tout comme indiqué ci-dessous. Pour de plus amples informations sur les circonstances dans lesquelles le conseil d’administration pourrait faire usage du capital autorisé et sur les objectifs que le conseil d’administration poursuivrait avec le capital autorisé, voyez également le rapport spécial mentionné au point 3 de l’ordre du jour de l’assemblée générale extraordinaire des actionnaires.	In order to allow the board of directors the flexibility to raise additional equity-based financing as and when the need may arise or an opportunity would present itself, the board of directors proposes that it be granted limited powers under the authorised capital to increase the Company’s share capital by a maximum amount of 100% during a term of five (5) years, all as further set out below. For further information on the circumstances in which the board of directors could make use of the authorised capital and the objectives that the board of directors would pursue with the authorised capital, see also the special report referred to in item 3 of the agenda of the extraordinary general shareholders’ meeting.
► Proposition de résolution:	►Proposed resolution:
L’assemblée générale des actionnaires décide de renouveler l’autorisation donnée au conseil d’administration d’augmenter le capital en une ou plusieurs fois, pendant une période de cinq (5) ans à compter de la publication aux Annexes du Moniteur belge de la présente autorisation, d’un montant total jusqu’à 100% du montant du capital de la Société, et ce conformément aux conditions et modalités fixées dans le rapport spécial du conseil d’administration établi conformément à l’article 7:199 du Code des sociétés et des associations, tel que visé au point 3 de l’ordre du jour de la présente assemblée générale extraordinaire des actionnaires. En conséquence, l’assemblée générale des actionnaires décide de supprimer l’article 6 “Capital autorisé” des statuts de la Société et de le remplacer par le texte suivant (la date mentionnée dans la sous-section entre crochets étant la date de l’assemblée générale approuvant le capital autorisé renouvelé, et le montant mentionné dans la sous-section entre crochets étant le montant du capital de la Société au moment de l’assemblée générale approuvant le capital autorisé):	The general shareholders’ meeting resolves to renew the authorisation to the board of directors to increase the share capital in one or several times, during a period of five (5) years as from the publication in the Annexes to the Belgian Official Gazette of this authorisation, with an aggregate amount equal to up to 100% of the amount of the share capital of the Company, and this in accordance with the terms and conditions set forth in the special report of the board of directors prepared in accordance with article 7:199 of the Belgian Companies and Associations Code, as referred to in agenda item 3 of this extraordinary general shareholders’ meeting. Consequently, the general shareholders’ meeting resolves to delete article 6 “Authorised capital” of the articles of association of the Company entirely and to replace it with the following text (whereby the date referred to in the sub-section between square brackets shall be the date of the general shareholders’ meeting approving the renewed authorised capital, and the amount referred to in the sub-section between brackets shall be the amount of the Company’s share capital at the time of the general shareholders’ meeting approving the authorised capital):
“Article 6 : Capital Autorisé	“Article 6: Authorised capital
Assemblée Générale Extraordinaire des Actionnaires de MDxHealth SA - Formulaire de vote par correspondance Extraordinary General Shareholders’ Meeting of MDxHealth SA - Voting by mail form	6/9
---	---
Le conseil d’administration est autorisé à augmenter le capital de la société en une ou plusieurs fois d’un montant total maximum de [100 % du capital de la société au moment de l’adoption du nouveau capital autorisé].	The board of directors is authorised to increase the share capital of the company on one or several occasions by a maximum aggregate amount of [100% of the company’s share capital at the time of the adoption of the new authorised capital].
---	---
Le conseil d’administration peut augmenter le capital par des apports en numéraire ou en nature, par l’incorporation de réserves, disponibles ou non, et par l’incorporation de primes d’émission, avec ou sans émission de nouvelles actions, avec ou sans droit de vote, qui auront les droits qui seront déterminés par le conseil d’administration. Le conseil d’administration est également autorisé à utiliser cette autorisation pour l’émission d’obligations convertibles ou de droits de souscription, d’obligations avec droits de souscription ou d’autres titres.	The board of directors may increase the share capital by contributions in cash or in kind, by capitalisation of reserves, whether available or unavailable for distribution, and capitalisation of issue premiums, with or without the issuance of new shares, with or without voting rights, that will have the rights as will be determined by the board of directors. The board of directors is also authorised to use this authorisation for the issuance of convertible bonds or subscription rights, bonds with subscription rights or other securities.
Cette autorisation est valable pour une période de cinq ans à compter de la date de publication aux Annexes du Moniteur belge d’un extrait du procès-verbal de l’assemblée générale extraordinaire des actionnaires de la société tenue le [date de l’assemblée générale approuvant le capital autorisé renouvelé].	This authorisation is valid for a period of five years as from the date of publication in the Annexes to the Belgian Official Gazette of an extract of the minutes of the extraordinary general shareholders’ meeting of the company held on [date of the general shareholders’ meeting approving the authorised capital].
En cas d’augmentation de capital décidée par le conseil d’administration dans le cadre du capital autorisé, toutes les primes d’émission comptabilisées, le cas échéant, seront comptabilisées conformément aux dispositions des présents statuts.	In the event of a capital increase decided by the board of directors within the framework of the authorised capital, all issue premiums booked, if any, will be accounted for in accordance with the provisions of these articles of association.
Le conseil d’administration est autorisé, dans l’exercice de ses pouvoirs dans le cadre du capital autorisé, à limiter ou à supprimer, dans l’intérêt de la société, le droit de préférence des actionnaires. Cette limitation ou suppression du droit de préférence peut également être faite en faveur des membres du personnel de la société ou de ses filiales, ou en faveur d’une ou plusieurs personnes autres que les membres du personnel de la société ou de ses filiales.	The board of directors is authorised, when exercising its powers within the framework of the authorised capital, to restrict or cancel, in the interest of the company, the preferential subscription rights of the shareholders. This restriction or cancellation of the preferential subscription rights can also be done in favour of members of the personnel of the company or of its subsidiaries, or in favour of one or more persons other than members of the personnel of the company or of its subsidiaries.
Le conseil d’administration est autorisé, avec droit de substitution, à modifier les statuts, après chaque augmentation de capital intervenue dans le cadre du capital autorisé, afin de les mettre en conformité avec la nouvelle situation du capital et des actions.”	The board of directors is authorised, with the right of substitution, to amend the articles of association, after each capital increase that has occurred within the framework of the authorised capital, in order to bring them in conformity with the new situation of the share capital and the shares.”
Assemblée Générale Extraordinaire des Actionnaires de MDxHealth SA - Formulaire de vote par correspondance Extraordinary General Shareholders’ Meeting of MDxHealth SA - Voting by mail form	7/9
---	---
► Instruction de vote:	► Voting instruction:
---	---
0 Pour / For	0 Contre / Against	0 Abstention
---	---	---
Le/la soussigné(e) confirme que les votes<br> susmentionnés s’appliquent à l’assemblée générale extraordinaire des actionnaires qui se tiendra le<br> vendredi 30 juin 2023. Dans le cas où l’assemblée générale extraordinaire des actionnaires susmentionnées<br> serait reportée ou ajournée, les votes susmentionnés s’appliqueront également à la ou à l’assemblée<br> générale des actionnaires qui seront tenues avec le même ordre du jour, le cas échéant:<br><br> <br><br><br> <br>☐ oui<br><br> <br>☐ non<br><br> <br><br><br> <br>Veuillez remplir la case appropriée. Une absence d’instruction ou si, pour quelque raison, il y a une absence de clarté à propos de l’instruction donnée, le soussigné sera supposé avoir choisi “oui”. Veuillez noter qu’aux fins de s’appliquer à telle assemblée subséquente, les titulaires de titres doivent s’enregistrer à nouveau pour cette assemblée.<br><br> <br><br><br> <br>Si, pendant l’assemblée, il y a des modifications<br> à une proposition de résolution ou une nouvelle proposition de résolution:^1^<br><br> <br><br><br> <br>☐ le/la soussigné(e) votera pour la<br>résolution modifiée ou nouvelle<br><br> <br>☐ le/la soussigné(e) votera contre la<br>résolution modifiée ou nouvelle<br><br> <br>☐ le/la soussigné(e) s’abstiendra<br>de voter sur la résolution modifiée ou nouvelle<br><br> <br>☐ la personne suivante sera consitutée<br>comme mandataire spécial, avec droit de substitution, pour voter au nom du/ de la soussigné(e) sur la résolution<br>modifiée ou nouvelle : le président du conseil d’administration de la Société^2^<br><br> <br><br><br> <br>^1^Veuillez cocher tel qu’approprié. Une absence d’instruction sera interprétée comme une instruction de voter pour la résolution modifiée ou nouvelle selon la manière supportée ou recommandée par le conseil d’administration de la Société.<br><br> <br><br><br> <br>^2^ Si le président du conseil d’administration de la Société est constitué comme mandataire spécial, le président (ou, le cas échéant, un autre administrateur, un employé ou un remplaçant désigné par la Société si le président est empêché d’assister à l’assemblée générale des actionnaires) vote dans ce cas sur les propositions de résolution modifiées ou nouvelles selon la manière supportée ou recommandée par le conseil d’administration. Veuillez noter que le président du conseil d’administration de la Société (ou, le cas échéant, le remplaçant du président) est un administrateur, un employé ou un remplaçant désigné de la Société et a donc un conflit d’intérêts potentiel tel que défini dans l’article 7:143, §4 du Code des sociétés et des associations.	The undersigned confirms that the aforementioned<br>votes apply to the extraordinary general shareholders’ meeting to be held on Friday, 30 June 2023. In case the aforementioned extraordinary<br>general shareholders’ meeting would be postponed or suspended, the aforementioned votes will also apply to the general shareholders’<br>meeting(s) that would be held having the same agenda, as relevant:<br><br> <br><br><br> <br>☐ yes<br><br> <br>☐ no<br><br> <br><br><br> <br>Please tick the appropriate box. In the absence of an instruction, or if, for whatever reason, there is a lack of clarity with regard to the instruction given, the undersigned shall be deemed to have selected “yes”. Please note that in order to apply for such subsequent meeting, holders of securities must again register for such meeting.<br><br> <br><br><br> <br>In case of amendments during the meeting to a<br> proposed resolution or a new proposed resolution:^1^<br><br> <br><br><br> <br>☐ the undersigned shall vote for the amended<br>or new resolution<br><br> <br>☐ the undersigned shall vote against the amended<br>or new resolution<br><br> <br>☐ the undersigned shall abstain from the vote<br>on the amended or new resolution<br><br> <br>☐ the following person will be appointed as<br>proxy holder, with the right of substitution, to vote on behalf of the undersigned on the amended or new resolution: the chair of the<br>board of directors of the Company^2^<br><br> <br><br><br> <br><br><br> <br><br><br> <br>^1^ Please complete as appropriate. An absence of instruction shall be tantamount to an instruction to vote for the amended or new resolution as will be supported or recommended by the board of directors of the Company.<br><br> <br><br><br> <br><br><br> <br>^2^ If the chair of the board of directors of the Company is appointed as a proxy holder, the chair (or, as the case may be, another director, an employee or a substitute designated by the Company if the chair is hindered to attend the general shareholders’ meeting) shall in such case vote on the amended or new proposed resolutions in the manner supported or recommended by the board of directors. Please note that the chair of the board of directors of the Company (or, as the case may be, his substitute) is a director, employee or substitute of the Company and therefore has a potential conflict of interest as defined in article 7:143, §4 of the Belgian Companies and Associations Code.
---	---
Ce formulaire de vote par correspondance sert également de notification au sens de l’article 7:134, §2, alinéa 3 du Code des sociétés et des associations pour l’assemblée générale extraordinaire des actionnaires de la Société qui se tiendra le vendredi 30 juin 2023.	This voting by mail form shall also serve as notification within the meaning of article 7:134, §2, paragraph 3 of the Belgian Companies and Associations Code with respect to the extraordinary general shareholders’ meeting of the Company to be held on Friday 30 June 2023.
---	---
Le soussigné confirme que la traduction anglaise du présent formulaire n’est qu’une traduction libre en anglais et à titre informatif uniquement, et que la version française prévaut sur la version anglaise.	The undersigned confirms that the English translation of the present form is a free English translation and for information purposes only, and that the French version shall prevail over the English version.
Fait à…………………………………….	Done at…………………………………….
Assemblée Générale Extraordinaire des Actionnaires de MDxHealth SA - Formulaire de vote par correspondance Extraordinary General Shareholders’ Meeting of MDxHealth SA - Voting by mail form	8/9
---	---
……………………………… 2023
---
(date)
……………………………………………………..
(nom / name)
……………………………………………………..
(signature)
Assemblée Générale Extraordinaire des Actionnaires de MDxHealth SA - Formulaire de vote par correspondance Extraordinary General Shareholders’ Meeting of MDxHealth SA - Voting by mail form	9/9
---	---

Exhibit 99.5

Free English translation for information purposesonly

MDxHealth SA

Limited Liability Company(société anonyme)

CAP Business Center

Zone Industrielle des Hauts-Sarts

Rue d’Abhooz 31

4040 Herstal, Belgium

VAT BE 0479.292.440 (RLP Liège, division Liège)

OUTSTANDING SHARES AND VOTING RIGHTS EXTRAORDINARY GENERAL SHAREHOLDERS’ MEETING to be held on Friday,<br> 30 June 2023, at 9:00 a.m.

This overview has been prepared by MDxHealth SA (the “Company”) in accordance with article 7:129, §3, 2° of the Belgian Companies and Associations Code.

On 6 June 2023, the total number of outstanding shares and voting rights of the Company amounted to 270,380,936.

Page 1

Exhibit 99.6

NEWS RELEASE –REGULATED INFORMATION

JUNE 5, 2023, 5:30 pm ET/ 23:30 CEST

MDxHealth Announces its Extraordinary

General Shareholders’ Meeting

IRVINE, CA, and HERSTAL, BELGIUM – June 5, 2023 – MDxHealth SA (Nasdaq and Euronext Brussels: MDXH) (the “Company” or “mdxhealth”), a commercial-stage precision diagnostics company, today invites the holders of securities issued by the Company to its extraordinary general shareholders’ meeting that will be held on Friday, June 30, 2023 at 9:00 a.m., Belgian time.

The items on the agenda of the extraordinary general shareholders’ meeting include the issuance of a new share option plan called the “2023 Share Option Plan” and the renewal of the authorization to the board of directors to increase the share capital within the framework of the authorized capital.

In order to participate to the extraordinary general shareholders’ meeting of the Company, the holders of securities issued by the Company must comply with article 7:134, §2, first indent of the Belgian Companies and Associations Code and the articles of association of the Company, and fulfill the formalities described in the convening notice. The convening notice, forms and other documents relating to the extraordinary general shareholders’ meeting can be consulted on the Company’s website.

The Company recommends holders of its securities to use e-mail for all communication with the Company regarding the general shareholders’ meeting. The Company’s email address for such communication is: agsm@mdxhealth.com.

About mdxhealth®

mdxhealth is a commercial-stage precision diagnostics company that provides actionable molecular information to personalize patient diagnosis and treatment. The Company’s tests are based on proprietary genomic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis and prognosis of urologic cancers and other urologic diseases. The Company’s U.S. headquarters and laboratory operations are in Irvine, California, with additional laboratory operations in Plano, Texas. European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands. For more information, visit mdxhealth.com and follow us on social media at: twitter.com/mdxhealth, facebook.com/mdxhealth and linkedin.com/company/mdxhealth.

For more information:

mdxhealth

info@mdxhealth.com

LifeSci Advisors (IR & PR)

US: +1 949 271 9223

ir@mdxhealth.com

***NOTE:***The mdxhealth logo, mdxhealth, Confirm mdx, Select mdx, Resolve mdx, Genomic Prostate Score, GPS and Monitor mdx are trademarks or registeredtrademarks of MDxHealth SA. The GPS test was formerly known as and is frequently referenced in guidelines, coverage policies, reimbursementdecisions, manuscripts and other literature as Oncotype DX Prostate, Oncotype DX GPS, Oncotype DX Genomic Prostate Score, and OncotypeDx Prostate Cancer Assay, among others. The Oncotype DX trademark, and all other trademarks and service marks, are the property of theirrespective owners.